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ABSTRACT 
 Label-free imaging of viruses and nanoparticles directly in complex solutions is 
important for virology, vaccine research, and rapid diagnostics. These fields would all 
benefit from tools that allow for more rapid and sensitive characterization of viruses. 
Traditionally, light microscopy has been used in laboratories for detection of parasites, 
fungi, and bacteria for both research and clinical diagnosis because it is portable and 
simple to use. However, virus particles typically cannot be explored using light 
microscopy without the use of secondary labels due to their small size and low contrast. 
Characterization and detection of virus particles therefore rely on more complex 
approaches such as electron microscopy, ELISA, or plaque assay. These approaches 
require a significant level of expertise, purification of the virus from its natural 
environment, and often offer indirect verification of the virus presence. A successful 
virus visualization technique should be rapid, sensitive, and inexpensive, while needing 
minimal sample preparation or user expertise. We have developed a disposable cartridge 
based platform for real-time, sensitive, and label free visualization of viruses and 
nanoparticles directly in complex solutions such as serum. To create this platform we 
  vi 
combined an interference reflectance imaging technique (SP-IRIS) with a sealable 
microfluidic cartridge. Through empirical testing and numeric modelling, the cartridge 
parameters were optimized and a flow rate of ~3 µL/min was established as optimal. A 
complex 2-dimensional paper based capillary pump was incorporated into the polymer 
cartridge to achieve a constant flow rate. Using this platform we were able to reliably 
show virus detection in a 20 minute experiment. We demonstrate sensitivity comparable 
to laboratory-based assays such as ELISA and plaque assay, and equal or better 
sensitivity compared to paper based rapid diagnostic tests. These results display a 
platform technology that is capable of rapid multiplexed detection and visualization of 
viruses and nanoparticles directly in solution. This disposable cartridge based platform 
represents a new approach for sample-to-answer label-free detection and visualization of 
viruses and nanoparticles. This technology has the potential to enable rapid and high-
throughput investigation of virus particle morphology, as well as be used as a rapid point-
of-care diagnostic tool where imaging viruses directly in biological samples would be 
valuable.  
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1. CHAPTER ONE: INTRODUCTION AND MOTIVATION 
1.1. Motivation 
Rapid point-of-care testing is paramount for identifying and controlling the spread 
of infectious disease[1]. The need for point-of-care testing was recently demonstrated 
during the spread of Ebola virus in West Africa in 2014-2015. An inexpensive test at the 
point-of-care should transform how a disease is controlled by allowing faster detection 
and containment.   
In order to be successful, a diagnostic test should be rapid, sensitive, and specific, 
and require minimal sample preparation, equipment, or user expertise. Common 
techniques for virus detection are Polymerase Chain Reaction (PCR), immunoassays, 
plaque assays, and lateral flow assays. PCR, Immunoassays and plaque assays all offer 
excellent sensitivity, but require significant infrastructure and expertise and are not easily 
deployable. Lateral flow assays are ideal for portability, however these often lack the 
sensitivity and specificity required. Lateral flow assays are regularly used for screening, 
but can require additional testing for verification[1]. Rapid, sensitive, and label free 
detection of viruses directly from serum without the extra sample preparation would be 
transformative and could greatly improve the treatment and control of future outbreaks. 
Bacteria, fungi, and parasites are all found in a size range where they interact 
strongly with visible light. The size of these particles and ease of visualization has made 
light microscopy an important tool for the study of infectious disease. It is standard 
equipment for microbiology labs and useful for the identification of bacteria, fungi, and 
parasites in clinical diagnosis situations as these microbes often have distinguishing size, 
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shape, and staining characteristics. In contrast, virus particles are too small to be seen 
using standard light microscopy. Thus, imaging of individual virus particles is typically 
performed using electron microscopy or atomic force microscopy, which require particle 
purification, significant levels of expertise, and are low throughput [2], [3]. Viruses can 
be detected in a standard light microscope only after labeling, which involves purification 
or genetic modification.   
The lack of an easy approach for the identification and counting of virus particles 
has limited researchers.  Assessment of individual particle size and shape in clinical and 
laboratory samples and virus stocks would benefit from a light microscopy technique that 
allowed high throughput measurements. Additionally, quantification of vaccine 
preparation monodispersity and uniformity would be more readily assessed with the 
development of techniques that allow the detection and characterization of large numbers 
of individual virus particles.  
The ability to use light microscopy for virus detection also has implications for 
improved point-of-care diagnostic approaches.  Light microscopy is globally established 
as an effective approach for diagnosing diseases such as malaria at the point of need[1]. 
The addition of the ability to carry out viral diagnostics on a similar platform could 
advance the diagnostic capacity of this readily used and cost-effective approach. 
Rapid detection of viruses is paramount for diagnostic applications. Many viral 
infections are diagnosed purely based on symptoms where as others require the collection 
and testing of bodily fluids. These tests typically require laboratory based infrastructure 
and can take hours to days to obtain results. The delay in test results inhibits treatment 
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and containment of diseases, which has significant effect on the prognosis and 
progression of the disease. These effects are compounded in low resource areas where 
patients may have to travel significant distances in order to be tested, making a return trip 
for results and treatment less likely. Techniques that offer these benefits would help 
improve patient care, and reduce the burden of the cost and time associated with current 
tests.  
Since the development of lab-on-a-chip technologies, their use has been explored 
for point-of-care testing. The potential advantages of being inexpensive and portable, 
while requiring low sample volumes, and rapid analysis, suits the needs for diagnostic 
testing well. However, these systems often require pressure or pumps to control fluid 
flow so they are not equipment free[1]. This, along with complexity and cost of 
fabrication, has hindered their widespread impact.  
The Ünlü Lab developed a technique known as Single Particle Interferometric 
Reflectance Imaging Sensor (SP-IRIS) that has been used to visualize individual viruses 
and nanoparticles[4]–[6]. This technique has been validated for sensitive and specific 
detection of viruses on the benchtop. However, it required a high level of user expertise 
and interaction. Additionally, the sensor had to be washed and imaged after drying in 
order to get the results. To further improve SP-IRIS from the bench top to a lab-on-a-
chip, sample-to-answer technique, there are several challenges that needed to be 
addressed. The first and foremost was to convert from dry imaging to imaging directly in 
solution. This would reduce the number of steps and user expertise required to run a test 
and help translate its use to a point of care setting. To accomplish this, the aim was to 
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model and create a disposable, capillary driven cartridge that allowed imaging of the 
sensor directly in solution during incubation without the need of additional equipment to 
run it. 
Here we describe the development of an enclosed virus detection approach that uses a 
disposable polymer paperfluidic cartridge that allows time-resolved counting of virus 
particles in complex solutions.  The cartridge was developed using a polymer cartridge 
with a unique paper based capillary flow technique. This allowed for an instrument free 
stand-alone cartridge. The cartridge was also modelled and validated using synthetic 
nanoparticles and vesicular stomatitis viruses. The microfluidic cartridge allows 
automated counting and analysis using a benchtop-sized light-microscope. Cartridge 
based virus detection showed good sensitivity in a short (20 min) timeframe. These 
advances result in a high performance platform and a disposable test which utilizes 
capillary based passive fluid handling, eliminating the need for pressure controllers or 
complex incubation machinery. Additionally, the disposable cartridge contains the 
sample to reduce exposure risk, and requires minimal sample preparation and no cold 
chain storage. 
1.2. Viral Hemorrhagic Fevers 
Viral hemorrhagic fever (VHFs) are a particularly devastating disease caused by a 
number of different RNA viruses. These viruses belong to five different families: 
Arenaviridae, Filoviridae, Bunyaviridae, Flaviviridae, and Paramyxoviridae[7]. Some of 
the viruses that cause VHFs are particularly notable because of their high mortality rate 
and rapid transmission, Ebola virus is one of these viruses. Both Marburg and Ebola 
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belong to the Filoviridae family. These viruses have multiple phenotypes, most notably 
the long filamentous particles that are characteristic to this family. Both have shown high 
mortality rates and epidemic potential. Additionally, since they most commonly occur in 
West and Central Africa, outbreaks are particularly difficult to identify at their early 
stages. The most recent outbreak in West Africa was the largest ever documented and 
demonstrates the potential impact of such diseases. The need for rapid diagnostic tools is 
highlighted in such events[8].  
Lassa virus is in the Arenaviridae family and has a smaller,spherical, and less 
characteristic shape than the Filoviridae. Lassa virus, however, is endemic to West Africa 
causing several hundred thousand cases annually[9]. The fatality rate is significantly 
lower than that of Filoviruses at only 1% - 2 %[9]. However the actual rate can be 
significantly higher for those with particularly severe cases. Being endemic, Lassa virus 
presents itself with a different set of difficulties for diagnosis. A rapid diagnosis that can 
distinguish between VHF caused by Lassa and one of the Filoviruses could be crucial in 
curtailing future outbreaks.   
1.3. Overview of This Dissertation 
 In this dissertation we present a disposable cartridge based platform for real-time 
detection of individual viruses in complex solutions. This platform is demonstrated 
through the implementation of a multiplex VHF panel for Ebola, Marburg, and Lassa 
virus. We investigate the ability to produce a biocompatible cartridge that utilizes 
manufacturable processes, as well as how to optimize the fluid processes that are required 
for such a test. This is detailed over the following six chapters.  
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 The second chapter presents the current technologies that are used for virus 
detection as well as newly competing technologies. This chapter describes the single 
particle interferometric reflectance imaging sensor (SP-IRIS) which is used as the sensor 
in the disposable cartridge including the underlying principles this technique utilizes. 
The third chapter goes over the methods used during this research. This includes 
the instruments used for the experiments. The virus detection and verification techniques 
are also described here along with the sensor and sample preparations.  
 The fourth chapter dives into the design process of the disposable cartridge. This 
includes materials selection, physical dimensions, objective selection, bonding techniques 
and other choices made when first attempting to develop this technique. The sensor 
optimization is also described in this chapter. 
 The fifth chapter is concerned with optimization of the surface capture of viruses 
using the disposable cartridge. This chapter shows real-time detection of viruses in both 
buffer and serum. The sensitivity and specificity of the developed assay are also tested, as 
well as demonstrating the multiplex capability. Finally, a model is developed for the 
cartridge using COMSOL followed by experimental validation of the model. 
 The sixth chapter deals with the design of a combined polymer paperfluidic 
cartridge. The cartridge uses capillary driven flow instead of a syringe pump to deliver 
the sample to the sensor. The effect of flow rate was experimentally explored and 
optimized for the design of the cartridge. The sensitivity and specificity in this cartridge 
was then also tested and compared to common virus detection techniques as well as 
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commercially available rapid diagnostics. Finally this test was demonstrated with bona 
fide Ebola and Marburg viruses. 
 Last, the seventh chapter offers a discussion of the progress made. This discusses 
relevant conclusions and as well as future work that was enabled by this research.  
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2. CHAPTER TWO: DETECTION TECHNIQUES 
2.1. Existing and Emerging Techniques for Single Particle Detection 
Many approaches for imaging viruses in solution are indirect approaches, such as 
purification followed by fluorescent labelling, or genetic modification of viral 
proteins[10], [11]. These approaches are useful for their virus tracking abilities but offer 
little to no information about the virus particle itself. Other techniques have been 
developed for virus and nanoparticle visualization based on light scattering and in-liquid 
transmission electron microscopy. There are also non-imaging approaches such as 
nanopore ionic current that can be used to gain information about viruses and 
nanoparticles [12]–[15]. 
Traditionally, direct imaging of viruses has been accomplished through electron 
microscopy. EM provides the gold standard in resolution but requires significant 
preparation, expertise, and often sample desiccation and degradation[16]. More recently, 
techniques have been developed that allow electron microscopy to be performed on 
samples in liquid[13]. Even with the notable images produced by electron microscopy, it 
is not uncommon to require immunogold labelling to verify that the objects in the image 
are the virus or particle you are looking for.  
A new technique that is rapidly becoming a gold standard for nanoparticle 
concentration measurements is the Nanoparticle Tracking Analysis (NTA) 
commercialized by Nanosight. This technique passes a laser beam through a sample 
chamber filled with a solution containing nanoparticles. The nanoparticles scatter light 
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and can be visualized by a microscope. This technique offers sizing through analysis of 
Brownian motion and easy concentration measurements. However, it has a fairly narrow 
dynamic range and cannot easily detect less than 1x108 particles/mL.  Additionally, in 
order to determine the chemical specifity of particles, or detect particles smaller than 
100nm, fluorescent labels are needed, which reduces the process to singleplex detection. 
Another technique that has been used to characterize particle size and 
concentration relies on changes in nanopore ionic current. This technique is a non-
imaging approach and offers no visualization, however it is capable of detecting and 
sizing dielectric nanoparticles in solution. This technique requires significant calibration 
and sample purification, and like NTA is unable to detect low concentrations of particles.  
New optical sensor systems have been developed in an attempt to meet these 
needs, such as surface plasmon resonance (SPR)[17], high-Q microcavities[18], and 
diffractive optics[19].  Each of these optical sensors has new and exciting attributes, but 
none has provided robust, direct, and deployable single particle visualization in a 
complex sample. 
Some of these techniques have proven to be useful in various research fields such 
as virology and vaccine development, but each has pros and cons related to sample 
through-put, cost, user expertise, and specificity[20], [21]. A technique that is capable of 
combining these benefits would be of high utility across a variety of fields.  
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2.2. Interferometric Detection of Metallic and Dielectric Nanoparticles 
  Label-free individual molecule and nanoparticle detection is the holy grail of bio-
sensing because it offers the most sensitive and direct information about the analyte. 
Nanoparticles from 10-100nm are typically only detectable with advanced optical 
techniques. Traditionally this problem has been overcome using fluorescent labels, which 
enable detection of individual nanoparticles or molecules on a fluorescent microscope. 
Fluorescent labels work very well but are vulnerable to photobleaching which makes 
them difficult to detect in low numbers.  
 The Single Particle Interferometric Reflectance Imaging Sensor (SP-IRIS) 
platform is a microscope that is capable of visualizing and counting individual dielectric 
and metallic nanoparticles down to 40 nm and 10 nm respectively. Biological 
nanoparticles on this size scale, such as viruses, can be directly visualized on the SP-IRIS 
platform without the need for additional labels.  
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The platform images the peak pixel intensity of the particle signal compared to 
the nearby background intensity. The particle signal is based upon the interference 
between the scattered field from the particle of interest and the reference field reflected 
off a layered sensor surface.  The optical system is optimized along with the optical 
properties of the target particles and the sensor. Figure 1 shows the particle signature of a 
single virus as seen by SP-IRIS. Due to the interference, particle signatures more closely 
resemble a coherent spread function, defined by the Bessel function, rather than the 
traditional point spread function seen in a non-interfering microscope. SP-IRIS utilizes 
custom particle detection software, developed in Matlab, to automatically identify 
particle associated local intensity maxima, and applies filters to remove non-diffraction 
limited peaks. 
To visualize nanoparticles, a silicon substrate with a thermally grown oxide layer 
is used to enhance the interferometric signal from individual particles[6]. Particles 
captured on the sensor surface have a much stronger signal than particles in solution at an 
  
                       Theoretical Signature   Experimental Signature 
Figure 1: Optical response of a nanoparticle on the SP-IRIS substrate 
Optical response of a nanoparticle 1a: showsA:The Si-SiO2 substrate creating interference with a single 
scattering nanoparticle. 1B: The theoretical particle signature of light scattered from a single nanoparticle as 
described by the bessel function. 1C: Shows the experimental particle signature of a single nanoparticle on 
the SP-IRIS substrate. 
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arbitrary distance from the surface due to the interference enhancement optimized by the 
silicone oxide spacer. This enhancement causes particles on the surface to become 
visible, while particles floating in solution do not hinder imaging. To understand how 
changing the medium affected the signal produced by the interaction of light with 
nanoparticles, the classical theory of induced dipoles on a non-absorbing particle was 
used. The quasi-static theory relates the strength of the induced dipole to the  
polarizability of the particle where r is the particle radius, εp is the particle 
permittivity, and εm is the surrounding medium permittivity[22]. In most non-magnetic 
materials the permittivity can be approximated by the square of the refractive index. By 
increasing the refractive index of the medium from n=1 in air to n=1.33 in water, the 
index contrast of the particle to the surrounding medium is reduced resulting in a weaker 
induced dipole.  
The intensity at the detector due to the scattered light alone is strongly dependent 
on size and becomes small very quickly. However, on a reflecting substrate, the signal is 
modified by mixing it with the strong reflected reference field. By doing this, the  
intensity at the detector depends on both the reference field and the scattered field, as 
well as the phase difference between them. By employing a reflecting substrate with very 
small nanoparticles, the pure scattered field |Esca|
2 is small enough to be considered 
Equation 1 
 
(1) 
Equation 2 
 
(2) 
Equation 3 
 
(3) 
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negligible. The reference field |Eref|
2 is essentially the background intensity and can be 
subtracted out of the image. The final term is the interference term which has an r3 
dependence on particle size instead of r6 dependence seen in pure scattering. However, 
this term is also modulated by the phase difference between the two fields, which is 
dependent on the path length difference between the centroid of the induced dipole and 
the reflected reference field. This phase difference can be optimized by controlling the 
silicon dioxide layer thickness to induce constructive interference and maximize the 
particle signal. 
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3. CHAPTER THREE: METHODS 
3.1. SP-IRIS Instrumentation 
 The SP-IRIS imaging platform is a brightfield, widefield microscope that uses a 
530nm green LED for sample illumination in a Koehler illumination configuration[6]. 
The sample is imaged with either a 50X .8 NA Nikon objective for dry samples, or a 40x 
0.9 NA Nikon objective for samples in liquid, onto a CCD camera (Retiga 4000R, 
  
 
Figure 2: SP-IRIS Imaging Platform 
The SP-IRIS imaging platform with green Thor Labs LED, Nikon Objective, ASI CRISP Focus System, and 
Retiga Camera.  
Camera 
Objective 
LED 
Sample 
Stage 
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Qimaging). The SP-IRIS imaging platform using three electronic stages to move the 
sample and focus on the surface of the sensor. A custom aluminum vacuum check was 
designed to hold the sensor. The version of the system seen in figure 2 uses the ASI 
CRISP autofocus system along with the z-axis stage incorporated into the optical 
components. The z-axis moves the objective up and down as opposed to moving the 
sample. The microscope system and image acquisition was controlled using a custom 
Matlab program developed by Jacob Trueb.  
 
3.2. nanoView Instrumentation 
Automated instrumentation was developed by David Freedman and George 
Daaboul at nanoView Diagnostics, in collaboration with this research. SP-IRIS images 
were acquired using the NVDX20 automated cartridge reader. The reader utilizes 
automated stages to control the position of the cartridge relative to the microscope 
objective in three axes. The instrument uses a 535nm wavelength LED light source to 
illuminate the substrate. The objective used on this imaging system is a 40X 0.75 NA 
Olympus objective with permanent cover slip correction set to correct for aberrations 
induced by 170 µm thick cover glass. Custom acquisition software is used to determine 
the antibody spots and automatically scan the desired number of spots at a user 
determined timer interval. To do this, a unique file is created for each cartridge which 
determines the location, type, and quality of the antibody spots based on proprietary spot 
quality criteria. For most experiments, the microarrays were scanned in their entirety 
once every two minutes, repeatedly for 20 minute experiments. The images saved were 
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then analyzed by custom software created by nanoView Diagnostics. This software takes 
a number of images at different levels of defocus around the nominal focal position of the 
surface of the sensor. These images are then compressed using a proprietary technique to 
increase the signal to noise ratio of the particles. Particles are detected on this processed, 
compressed image. The peak normalized pixel intensity is then calculated as compared to 
the local particle free background intensity. This peak intensity is used to characterize the 
particle size. 
 
3.3. Rapid Diagnostic Tests 
Many different types of rapid diagnostic tests exist for detection of viruses, 
proteins, or bacteria, however by far the most prevalent is the lateral flow immunoassay 
or latera flow test. These types of tests rely on molecular recognition of the analyte within 
a porous media, typically some form of paper, along with a colorimetric response. The 
simplest form of lateral flow test is a homogeneous assay. In a homogenous assay the 
sample containing the analyte is mixed with a reagent that contains a conjugated particle 
which allows for the colorimetric readout. These are commonly blue latex particles or 
nanometer size gold particles which appear red due to optical resonance[23]. After the 
reagent is mixed with the sample, it is added to one end of the absorbent material. The 
paper material acts as a bed of capillary tubes and draws the fluid across its length 
passively via capillary force. The capture antibody is embedded in the porous paper 
material in the form of a spot or a line. When the analyte is present in the sample, it 
builds up on the capture antibody causing an aggregation of the colorimetric particle. 
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When enough particles build up, the color becomes visible to the naked eye, or in some 
cases to an automated reader. 
Two lateral flow assays that are available under Emergency Use Authorization by 
the U.S. Department of Health and Human Services for the detection of Ebola Zaire virus 
are the Corgenix ReEbov Rapid Antigen Test, and the OraQuick Ebola Rapid Antigen 
Test. Both tests rely on antibody capture of the VP40 viral matrix protein found in the 
virus which requires lysing of the virus prior to detection. The sample is then added to the 
lateral flow test strip and visual colorimetric results appear in about 20 minutes. These 
tests represent the pinnacle of current inexpensive field deployable diagnostics, but both 
lack in sensitivity and quantitative results. 
 
3.4. Viral Infection and Virus Detection Techniques 
3.4.1. Enzyme Linked Immunosorbent Assay (ELISA) 
ELISA is one of the most common wet bench techniques for detecting viruses or 
pathogens[24]. This technique uses adsorbed antibodies in the bottom of a microwell 
plate coupled with a signal amplification enzyme to detect the presence of an antigen. For 
the detection of the Ebola GP-pseudotyped vesicular stomatitis virus, Wells of a 96-well 
microtiter plate were coated with 13F6 anti-Ebola GP antibody to a concentration of 10 
ug/mL in carbonate/bicarbonate buffer. Wells were blocked with 1% bovine serum 
albumin (BSA) in PBS for one hour, then serial dilutions of rVSV-ZEBOV in FCS were 
added to wells in triplicate for one hour. Wells were washed three times with PBST and 
blotted on a paper towel to remove excess buffer. A horseradish peroxidase-conjugated 
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anti-Ebov GP secondary antibody was added at a concentration of 50 ng/mL in 1% BSA 
in PBS for thirty minutes, followed by three washes in PBST. For this assay, a QuantaBlu 
Fluorogenic Peroxidase Substrate Kit (Thermo Fisher, 15169) was used. After blotting 
plate on paper towels to remove excess wash buffer, 100 µL of QuantaBlu WS was added 
to each well and incubated at room temperature. After 60 minutes, 100 µL of QuantaBlu 
Stop Solution was added to wells to stop the peroxidase activity. The relative 
fluorescence units (RFU) for each well were then read using a Tecan plate reader at an 
excitation of 325nm and an emission maximum of 420nm. All ELISA results presented 
here were conducted by Erik Carter of the Connor lab. 
 
3.4.2. Plaque Assay 
Perhaps the most common virus quantification technique is the plaque assay. 
Plaque assay is a petri dish based technique that indirectly counts the number of viruses 
in a sample by measuring the number of plaque forming units in a sample[25]. In this 
technique a monolayer of host cells are grown in a petri dish prior to being infected by 
virus samples at varying dilutions. Following infection they are then covered over with a 
semi-solid media such as agar. Host cells infected with the virus will lyse and spread the 
virus to neighboring cells, which will continue the process infecting nearby cells. These 
areas devoid of live cells are known as plaques and each one represents the presence of 
an infectious virus unit, or plaque forming unit (PFU). This technique reports viral 
concentration in plaque forming units per milliliter (PFU/mL). 
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For the quantification of virus samples done in the following experiments, plaque 
assays were performed by seeding 6-well tissue culture plates with Vero E6 cells to be 
90% confluent on day of assay. Ten-fold dilutions of each virus sample were prepared in 
serum-free DMEM and kept on ice. Vero cells were washed three times with PBS and 
then inoculated with 100uL of each stepwise dilution and incubated at 37ºC for 1.5 hours. 
Plates were rocked back and forth every 15 minutes to ensure even dispersal of virus over 
cells. Following incubation, a 1:1 mixture of 2X DMEM at 37ºC and 2% agar in PBS at 
55ºC was prepared and wells were overlaid with 4 mL of the mixture. Plates were 
incubated at 37ºC with 5% CO2 for ~30 hours, then fixed with 4% formaldehyde and 
stained with 1% Crystal Violet. Plaque assay experiments were conducted by Erik Carter. 
 
3.4.3. Quantitative Polymerase Chain Reaction (qPCR) 
qPCR is a highly sensitive technique for measuring the presence of nucleic acid 
targets in solution. This technique is a real-time fluorescent measurement of the 
amplification of a specific DNA or RNA sequence using. PCR uses a thermal cycler to 
dehybridize nucleic acid strands and then uses single nucleotides doubling the number of 
targets in solution. The number of cycles required for the fluorescence to be reported by 
the photodetector is a measurement of the number of starting targets.  
In these experiments serial dilutions of rVSV-ZEBOV were processed to isolate 
viral RNA using a Zymo Viral RNA Extraction Kit (Zymo Research, R1035). RT-PCR 
was performed on the samples using a SuperScript III One-Step RT-PCR Platinum Taq 
HiFi Kit (Invitrogen, 12574-035) and the reaction was carried out and analyzed using a 
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Biorad CFX96 Real-Time C1000 Thermo Cycler (Biorad, 1855096). All qPCR data 
presented in this document was performed by Erik Carter. 
3.5. Sensor and Sample Preparation 
3.5.1. Surface Preparation 
Surface preparation is paramount to biosensor development. A perfect surface will be 
both sensitive and specific, with low background noise, and good stability. The substrates 
used for the sensors were from Silicon Valley Microelectronics. The substrates used in 
this sensor are polished silicon with thermally grown oxide on one side. The thickness of 
the oxide layer is controlled to optimize the signal (contrast) enabling highly sensitive 
detection and counting of nanoparticles. An oxide thickness of 100nm is used for imaging 
in air, while 30nm thickness is used for in liquid imaging. The thermal oxide provides a 
commonly used surface for functionalization.  
There are several different techniques that can be employed for functionalizing a 
glass surface. These are often characterized into three groups: physical adsorption, 
covalent bonding, and affinity based immobilization[26]. Physical adsorption is the least 
well controlled of the processes utilizing weaker, Van Der Waals or ionic interactions 
between the protein and the surface. Physical adsorption is the simplest of the 
approaches, but offers the least control and the highest variability. Additionally, because 
of the weaker interactions, it is more likely for the proteins to leave the surface during an 
experiment. 
Covalent bonding offers a very strong attachment method. This type of 
functionalization is typically performed using epoxides, aldehydes, and N-hydroxy 
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succinimidyl (NHS) esters that bond to the primary amines of amino acids. This type of 
attachment regime can cause loss of functionality due to how the protein is bound to the 
surface.  
The last approach is through covalent affinity based immobilization. This 
technique uses specific interactions such as surface coatings of protein A, protein G, 
streptavidin, or DNA to interact with a native or modified antibody. This allows 
orientation control of the antibody and the potential for increased flexibility of the probe. 
These techniques have been shown to improve sensitivity of assays and spot quality at the 
expense of an additional preparation step[27].  
The sensor surface in these experiment was coated in an anti-fouling 3-D polymer 
copoly(N,Ndimethylacrylamide (DMA) - acryloyloxysuccinimide (NAS) - 
3(trimethoxysilyl) propylmethacrylate (MAPS))[28]. This polymer was chosen because it 
has good anti-body immobilization characteristic with very low non-specific binding[28]. 
The DMA group undergoes adsorption with the glass surface while the NHS group 
covalently binds the amines of the protein, all while the polymeric matrix allows for 
flexibility in attachment to the antibodies.  
3.5.2. Microarray Printiing 
A Scienion S3 SciFlexArrayer was used to create an array of antibody probes. 
The micro-printer is capable of repeatedly producing droplets between 200-300 picoliters 
and placing them in a grid with accuracy of ~20um. A typical droplet of 250 pL will 
created a spot of ~150µm diameter. The sensors were left for 12 hours to allow time for 
the antibodies to immobilize on the surface.  Any unbound antibody was then washed 
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with 1X PBST (0.1% Tween-20) followed by Nano- pure filtered de-ionized water and 
dried under a nitrogen gun. Arrayed sensors were stored refrigerated at 4°C and used 
within 7 days.  
Monoclonal antibody against VSV glycoprotein was produced from hybridoma 
cells for use as a negative control antibody. Anti-ebola glycoprotein antibody (13F6) was 
provided by Larry Seitlin at Mapp biopharmaceutical. For a negative control antibody, an 
antibody against native vesicular stomatitis virus (VSV) was used (8G5)[6].  All 
antibodies were spotted in PBS with 25mM trehalose at a protein concentration of 2-4 
mg/mL.  Monoclonal antibodies against Marburg virus were provided by Dr. Ayato 
Takada (Hokkaido University). The monoclonal antibody used for detection of Lassa 
virus was 8.9F, and was provided by Dr. James Robinson (Tulane University) and Luis 
Branco at Zalgen therapeutics. Antibody selection was carried out by Elif Seymour. 
3.5.3. Virus Sample Preparation 
Virus stock was provided in cell media solution. All limit of detection 
experiments were conducted from a single stock sample serially diluted.  For dilution 
experiments all virus titers were confirmed using plaque assay. Experiments conducted in 
buffer used 1X PBS with 1mg/mL bovine serum albumin added. Fetal bovine serum was 
purchased from ATCC (#30-2020). All active pumping experiments were conducted in a 
cartridge with fluid controlled by a Harvard Apparatus PhD 2000 syringe pump. Just 
prior to insertion of the sample, the cartridge was filled with a blank sample (PBS or 
FBS) to allow imaging before virus accumulation occurs. The recombinant vesicular 
stomatitis viruses that express the native Ebola glycoproteins were created by inserting 
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the protein cDNA into an independent transcription start/stop sequence between the M 
and L genes in a VSV genome where the VSV glycoprotein sequence had been removed. 
VSV psuedotyped variants for Marburg and Lassa virus were created in a similar fashion. 
All VSV samples were produced in the Connor lab by Erik Carter. Ebola virus samples in 
cell media were inactivated using gamma irradiation and provided by Hideki Ebihara at 
Rocky Mountain Laboratories.  
3.5.4. Bio-Safety Level 4 Experimentation  
Bona fide virus testing was conducted using Ebola Virus, Zaire strain-variant 
Mayinga. This was performed at the bio-safety level 4 facility of University of Texas 
Medical Branch in Galveston, Texas. All experiments were carried out by Krystle N. 
Agans. To carry out these tests, stock virus solution in cell media was diluted using 100% 
FBS. Bona fide Zaire Ebola virus (EBOV) used in this study was the Mayinga variant 
from isolate Ebola virus H.sapiens-tc/COD/1976/Yambuku-Mayinga (passage 3; Vero 76 
(ATCC, CRL-1587)). This research was made possible due to the collaboration with 
Chad E. Mire and Thomas W. Geisbert at the Galveston National Laboratory of 
University of Texas Medical Branch in Galveston, Texas. 
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4. CHAPTER FOUR: DISPOSABLE CARTRIDGE DESIGN 
The fourth chapter deals with the development of interference enhanced detection 
of viruses and nanoparticle in a liquid environment using the SP-IRIS sensor system. The 
primary hurdle is the design of a disposable flow cell that allows visualization of viruses 
and nanoparticles using a high NA, short working distance objective. This includes 
material selection, bonding approaches, and geometric constraints.  In addition, sensor 
fabrication and optimization for in solution (n=~1.33) measurements will be addressed. 
4.1. Engineering a Disposable Cartridge for In Solution Imaging of Viruses and 
Nanoparticles 
A disposable cartridge for detection of individual viruses using SP-IRIS has many 
physical limitations that need to be taken into account. The cartridge needs to be self-
contained, manufacturable, optical quality, non-fouling, utilize room temperature bonding 
for microarray chip addition, fit beneath a short working distance objective, all while 
maintaining the sensitivity of the assay. These factors all have to be taken into account 
when considering how to create the cartridge.  
Starting with a standard #1.5 coverglass (~170µm) spaced with a thin (~25µm) 
spacer of tape to model a flow channel beneath different objectives were tested. The 
objective used for dry imaging is a 50X 0.8 NA air immersion objective. The system 
required a high NA (<0.7) and fairly high magnification to ensure sufficient sampling of 
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the particle signature. Table 1 shows the different Nikon objectives tested and what 
criteria was used for deciding. The standard objective used for dry imaging had no 
spherical aberration correction in the form of coverslip correction. Both the 40x 0.9NA 
and 60x 1.2NA had variable correction collars that allowed for fine tuning the aberration 
correction to get the best image. However, the 60x 1.2NA used water immersion, had a 
smaller field of view, very short working distance, and was significantly more expensive. 
Due to these drawbacks, the 40x 0.9NA objective was used for the remainder of the 
testing.  
The optical window material was another important decision. Initial tests utilized 
a glass coverslip which showed sufficient image quality, but glass is difficult and 
expensive to integrate into a cartridge. Multiple different optical quality plastics and glass 
 
Figure 3: Model of fluidic cartridge. 
Cross-sectional model which demonstrates the fluidic path (in blue), the SP-IRIS sensor (in gray) and the 
polymer flow cell and window (in yellow), not shown to scale. 
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were tested for imaging. Although glass showed very good particle image quality, it is 
significantly more expensive to integrate into a cartridge. In addition to the cost and 
manufacturability, there was some concern with broken glass in a BSL-4 setting which 
would be a major biocontainment concern. Although cyclic olefin copolymer showed 
excellent image quality, it is an expensive and proprietary plastic which raised concerns 
for future production of the cartridge. For that reason Polycarbonate was chosen from the 
plastics tested and was utilized for the remainder of the builds.  
Table 1: Objective Selection 
 50x 0.8NA 40x 0.9NA 60x 1.2NA 40x 0.75NA 
Particle Contrast - ++ +++ + 
Field of View ++ +++ + +++ 
Coverslip correction - +++ +++ ++ 
Working Distance +++ ++ + ++ 
Immersion Media Air Air Water Air 
Cost $ $$ $$$$ $ 
 
Table 2: Window Material Selection 
 Glass Polycarbonate COC PET 
Particle Contrast +++ ++ ++ - 
Manufacturability + +++ ++ +++ 
Robustness + +++ +++ +++ 
Cost $$$ $ $$ $ 
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Determining the best way to produce a disposable cartridge that fit within the 
working parameters was another engineering decision. The working distance of the 
chosen objective was 300µm which made integration of the fluidic channels and imaging 
window a difficult task. Several options were tested for early prototyping including soft 
lithography with PDMS, soft embossing of thermoplastics, and polymer laminate 
construction. PDMS allowed us to begin testing quickly with little overhead for 
production, but has significant drawbacks with integrating the sensor into a cartridge that 
can be imaged. It is difficult to manufacture and create a robust, thin imaging window. 
Soft embossing of thermoplastics created a more manufacturable cartridge, but was 
difficult to integrate with the sensor because the imaging window was a separate piece. 
Several other approaches that were tested included deep reactive ion etching to create 
through holes in the sensor chip for the fluid path. A polymer laminate construction was 
also created using a laser cutter and PSA layers and was found to be easiest to integrate 
with the design constraints. The imaging window was simply a layer in the construction 
Table 3: Cartridge Construction 
 PDMS Soft Embossing 
Polymer 
Laminate 
Ease of Prototyping +++ + ++ 
Integration of sensor + + +++ 
Integration of window - + +++ 
Feature size +++ + ++ 
Manufacturability - ++ +++ 
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and polymers and PSA both offered approaches for bonding the sensor. Based on these 
findings a polymer laminate construction was chosen for the cartridge. 
 The sensor was spotted with antibodies prior to being bonded to the 
cartridge, which means the bonding method was restricted to a room temperature 
technique that did not off-gas or chemically interfere with the antibodies in anyway. The 
bonding methods that were tested are shown in table 4. The use of a PSA is by far the 
simplest option because it allows final assembly of the cartridge after spotting without the 
need for precision gluing. Both the cyanoacrylate and acrylic PSA did not form a robust 
bond and were not usable, but the silicone PSA formed a strong liquid tight bond. The 
use of a PSA also allowed us to control the thickness of the channel.  
 There is an interplay between channel geometry (height and width) and flow rate 
on the effect of virus binding. It was determined that a single pass of fluid was preferable 
over recirculation of the sample since it decreased the complexity of the assay. Since the 
sample volume was limited to ~100µL, and the experimental time to ~25 minutes, the 
flow rate has a maximum of 4µL/min. Additionally, the array size of 16 spots limits the 
minimum dimensions of the channel. Adding a small buffer region between the edge of 
the channel and the spots, for placement of the chip and potential bubble entrapment, the 
Table 4: Bonding Methods 
 Cyanoacrylate UV Epoxy 
Silicone 
PSA 
Acrylic 
PSA 
Bonding Strength - +++ +++ - 
Manufacturability + + +++ +++ 
Biocompatibility + +++ ++ ++ 
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width of the channel was set at 2000µm wide. Working with polymer laminates, the 
thinnest repeatable channel thickness was 25µm. Thus, the channel geometry was 
determined as a combination of physical constraints imposed by assay parameters, 
manufacturing capability, and assay optimization. 
4.2. Interference Layer Optimization for In Liquid Visualization of Native 
Viruses and Nanoparticles 
Single virus and nanoparticle visualization in air has been well established by the 
Ünlü lab[4]–[6]. This was accomplished by utilizing a narrowband LED with a 530nm 
(green) peak wavelength as the illumination source on 100nm Si-SIO2 substrate. This 
effectively turns the substrate into a common path homodyne interferometer, in which the 
phase difference is controlled by the thickness of the SiO2 layer thickness. For 
measurements in air with this objective we have shown for a 100nm dielectric particle, 
~100nm SiO2 layer thickness can be used. However, the phase difference is affected by 
the NA of the objective, as well as the size of the particle, and the height of the particle 
above the surface. For in liquid measurements where the sensor is embedded in solution 
beneath a layer of cover glass, a cover glass corrected objective needs to be used. The 
correction on the objective is used to compensate for spherical aberrations induced by the 
different path lengths traveled by high angle light passing through the cover glass and 
liquid layer. For this a 40X 0.9 NA Nikon objective with variable aberration correction 
was chosen. 
Given the relatively high NA objective, it was expected that the optimal oxide 
would be thinner than 100nm that was used for dry imaging. To test this, individual SP-
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IRIS sensors were etched using dilute buffered oxide etch in 10nm increments from 
100nm down to 0nm (bare Si). Each of these chips was coated in the anti-fouling 
copolymer that is used to promote protein adsorption and anti-Ebola spots were arrayed 
on the surface. All chips were incubated in PBS spiked with rVSV-ZEBOV to create a 
uniform coverage of viruses on the spots. Following that, each chip was imaged in 
solution beneath 125µm polycarbonate cover glass and 25µm of PBS.  
To ensure that the optimal focus was achieved, a stack of images ranging 4µmin 
0.2µm steps around the nominal focus was acquired. Individual particles were tracked 
through the stack of images and the contrast for each particle was recorded for each 
image in the stack. This produced a standard defocus curve representing the particles 
response with respect to change in z-location shown in figure 4A. Using the peak contrast 
value for each SiO2 thickness tested, a curve showing the particle response with respect 
to SiO2 thickness was generated. Figure 4B shows the impact of altering the SiO2 layer 
 
Figure 4: Contrast response of single particle with respect to SiO2 thickness 
4A: The peak contrast defocus response of a single virus on the SP-IRIS substrate in liquid over a range of 
z positions ranging +/- 2 microns. 4B:The average peak contrast response of single viruses on different 
thickness SiO2 layers. 
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thickness on the particle response. The peak particle contrast increases as the oxide layer 
increases until ~30nm and then the peak signal begins to degrade as the phase shift 
between the two fields begin to interfere destructively. The optimal layer thickness for 
visualizing 100nm virus particles in liquid is ~30nm. This is significantly thinner than the 
100nm SiO2 layer used previously for imaging in air.  
To validate this initial finding, 104 nm polystyrene beads and rVSV-ZEBOV 
were immobilized on the surface of both 100nm and 30nm chips. The 100nm chips were 
imaged in air whereas the 30nm chips were imaged in liquid on the same instrument. 
Figure 5 shows the signal of the 104nm polystyrene beads bound to the substrate in air 
have a mean contrast 6.7% greater the local background. The signal of the same particle 
 
Figure 5: Comparison of virus signature in air and in liquid 
Figure 5 shows 104nm polystyrene beads imaged in air and water as well as virus particles in air and water. 
Each white dot is the image of a single nanoparticle or virus. A histogram shows the contrast of the particles 
compared to the local background in both air and water. 
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type imaged in liquid was lower but still clearly detectable over the background with an 
average contrast of 1.7% more than the local background. This shows that although there 
is a reduction in contrast of nanoparticles when imaged in a liquid environment they are 
nevertheless clearly detectable.  
The signal from virus particles imaged dry appeared similar to the polystyrene 
bead with an average contrast 8.0% above the nearby background (figure 5). When the 
same type of viruses were imaged immersed in liquid, they had a similar reduction to the 
polystyrene particles, showing a mean contrast of 2.1% more than the local background. 
Expectedly, viruses show a similar reduction in contrast to polystyrene beads. This 
validation suggested there is sufficient information for robust label-free, wide field 
visualization of nanoparticles and viruses in a liquid environment. 
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5. CHAPTER FIVE: SURFACE CAPTURE OPTIMIZATION AND 
MODELLING 
The fifth chapter deals with the use of the disposable cartridge for detection of 
viruses in solution. The real time detection modality will be explored as well as testing 
the performance of the sensor in both PBS and FBS. Finally, the ability to detect multiple 
analytes in a single test will be demonstrated. 
 
5.1. Real Time Detection of Individual Viruses 
Once we were able to show the ability to visualize viruses and nanoparticles in 
solution, we wanted to further validate the system by showing dynamic detection. A PBS 
buffer solution was spiked with virus and injected into the cartridge, using a syringe 
pump, which housed the detection sensor with virus specific antibodies. The chip surface 
was imaged every 30 seconds. After imaging, particles were detected using custom 
particle detection software. The software allows debris in the initial images to be counted 
and subtracted from subsequent virus counts. Viruses on the sensor appeared as bright 
dots seen in figure 6 (compare to insets at t=0 and t=4), the number of bound particles 
increased over the 16 minute experiment presented here. The red inset in figure 4 shows a 
particle that would not be counted as a virus because it was present in the initial image 
before the experiment started. Additionally, different size particles have different 
contrast, allows us to discriminate based on size and lets us filter to restrict counting to 
those dots which appear as the expected size of the virus particle. This analysis showed 
viruses beginning to be captured at T=0.5 minutes and an increasing number of particles 
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detected over the total duration of the experiment (from T=0 to T=16 minutes) shown in 
Figure 6.  
 
5.2. Virus Detection Sensitivity in Buffer  
Having validated the ability to directly detect viruses as they were captured on the 
sensor, we then evaluated the specificity and performance of our system. We did this by 
performing a dilution experiment using rVSV-ZEBOV in PBS with 1% BSA and 
evaluated to lowest detectable concentration. Virus detection occurred by imaging a 
single antibody spot in the microarray at a set time interval. Each image was then 
analysed using the particle detection software to create a curve of virus count versus time. 
This number was reported as total number of viruses captured on one spot. 
 For the lower limit of sensitivity experiment, 6 dilutions were used from the stock 
virus solution (~107 PFU/mL) with samples ranging from just one 10 fold dilution (~106 
 
Figure 6: Real-time detection of individual viruses 
Figure 6 shows an antibody spot imaged before the sample incubation begins, and images taken at 4 
minutes and 16 minutes, showing the accumulation of viruses on the surface. The black insets show a 
close up of the spot and the individual viruses. The red inset in the first time point (T=0) shows debris 
that is present at the beginning of the experiment. These are not counted as viruses because they are 
present before the incubation begins. 
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PFU/mL) to a 106 fold dilution (~10 PFU/mL). We also included a blank sample with no 
viruses. An excess of the each dilution was made and part of it was inserted into the 
cartridge using a syringe pump. An aliquot of each dilution was also used to determine 
virus concentration via plaque assay.  During the incubation, the sample flowed across 
the chip at 1 µL/min, while images were acquired every 30 seconds. 
The complete dilution curve in PBS with 1% BSA is shown in figure 7A. The 
most concentrated sample, 1x106 PFU/mL, showed rapid accumulation of viruses binding 
to the surface. There was a short period of linear virus accumulation, after which 
saturation occurred near the 30 minute mark. Low concentration solutions had slower 
virus accumulation but approached similar saturation numbers. This saturation occurs as 
a result of the inability to distinguish individual particles when they are bound closely to 
one another on the sensor surface. Despite this phenomenon, high concentration samples 
can still be differentiated by their initial binding rate.  Figure 7b shows the lower 
concentration of viruses were still clearly detectable. This figure shows the samples of 
1x103 PFU/mL and below. Figure 7B shows that even at 100 PFU/mL the signal is 
 
Figure 7: Real-time counting of single viruses in PBS 
7A: The accumulation of viruses being imaged on the sensor for a serial dilution ranging from 1x106 PFU/mL 
down to a blank sample. The high concentration samples show a very rapid accumulation of viruses followed 
by a saturation of the sensors. 7B: shows the lower concentrations expanded and shows a linear accumulation 
of viruses and a limit of detection of 100 PFU/mL in less than sixty minutes. 
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differentiable from the blank sample in fewer than 30 minutes. At low concentrations, the 
virus binding remains linear for the entirety of the experiment. The lowest concentration 
tested was only 10 PFU/mL and was not distinguishable from a sample of PBS that 
contained no virus. Our previous work has shown the lowest concentration detectable in 
air to be 5x103 PFU/mL[5]. This work validates rapid detection as well as a lower limit of 
detection.  
 
5.3. Virus Detection and Quantification in Complex Solutions 
To further validate the cartridge, we wanted to explore the effect of other media, 
such as serum. The ability to use the cartridge directly with serum would allow us to 
reduce sample preparation. To test the performance of the cartridge in serum, an 
additional dilution experiment was performed, again using rVSV-ZEBOV. This 
experiment followed the same protocol previously described, with the PBS replaced with 
FBS. 
 The results of the experiment with FBS are shown in Figure 8A, which closely 
resembles the previous experiment with PBS. The highest concentration again shows a 
very rapid accumulation of viruses as well as a reduction in binding rate as more viruses 
accumulate on the sensor. The lower concentrations also show a linear dependence for 
the duration of the experiment. The lower limit of detection in serum for this experiment 
was also 100 PFU/mL, similar to the results in PBS. This validates the use of the 
cartridge for detection of viruses directly in complex media such as serum. Even though 
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the media contains proteins and other bio-nanoparticles, and is not perfectly optically 
clear, imaging was still possible without a loss of signal.  
 These curves also show there is a strong concentration dependence on the virus 
accumulation rate. To quantify this signal, a first order linear curve was fit to the virus 
count versus time for each concentration. At high concentrations that showed non-linear 
behavior, the linear region in the first several minutes of the experiment were used, as 
shown in figure 8B. This binding rate was reported in Figure 8C measured in viruses 
bound per minute per mm2 and plotted against the log dilution of the stock virus sample. 
Each dilution was also tested via plaque assay and reported in PFU/mL. The virus 
 
Figure 8: Real-time virus detection and quantification in serum 
Figure 8A shows the accumulation of rVSV-ZEBOV viruses for a serial dilution. Images were taken directly 
in 100% FBS without wash or labelling. Figure 8B shows the linear binding region in the first 5 minutes of 
the binding curve for a high concentration of virus plotted as viruses capture per mm2. Figure 8C shows how 
the binding rate (slope in particles/mm2/minute) for rVSV-ZEBOV in PBS and FBS shows a linear response 
to virus concentration. This is shown along with plaque assay (PFU/mL) to show that this may be used as a 
means of quantifying viral concentration. Plaque assay zero values are reported as 10-1. 
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binding rate for this cartridge showed a linear response over a 4 orders of dilution in PBS 
and FBS. This results show that this cartridge can provide quantitative results over a wide 
dynamic range while still maintaining high sensitivity. 
 
5.4. Real-Time Multiplex Detection of Viral Pathogens 
The ability to rapidly detect multiple agents in a single test, with minimal sample 
preparation, is critical to bio threat and outbreak containment as well as screening for 
common diseases [29], [30]. Testing for multiple antigens in a single test often reduces 
the total time needed for testing, while also decreasing the cost of the test. However, 
multiplex testing increases the potential for cross-reactivity between conditions which 
can lead to false positive results. We are able to simultaneously image up to 9 spots at a 
 
Figure 9: Multiplex Virus Detection  
Figure 9 shows the detection of rVSV-ZEBOV, rVSV-MARV, and rVSV-LAS sequentially in a single field 
of view. The negative control antibody demonstrates specific detection of multiple virus types from a single 
sample in one field of view. This demonstrates the use of this cartridge as a rapid viral haemorrhagic fever 
panel.  
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time and fit upwards of 100 different conditions in a single test. By using automated 
stages, 10’s of conditions can be tested in real-time with digital sensitivity.  
Figure 9 shows a test of 4 spots being imaged in a single field of view. This shows 
a viral hemorrhagic fever panel with detection of rVSV-ZEBOV, rVSV-MARV, and 
rVSV-LASV as well as negative control spots that are specific to wild-type VSV. Each 
pseudotype virus flowed into the channel sequentially with a wash step between to 
remove any of the previous virus samples. The first region shows pure buffer with no 
binding to any of the conditions. The next region shows the presence of rVSV-ZEBOV 
entering the channel at about 25 minutes followed by a wash step. This is then followed 
by rVSV-MARV at approximately the 50 minute mark, and finally rVSV-LASV around 
75 minutes. There is mild cross reactivity between rVSV-ZEBOV and rVSV-MARV 
which is not unexpected due to the overwhelming similarity between the two viruses. 
Each antibody specifically recognizes a single virus which demonstrates the capability 
RT-SPIRIS to perform very large scale label-free real-time detection with digital 
sensitivity. Multiplex testing was conducted in collaboration with Elif Seymour. 
5.5. Modelling of functionalized nanoparticle adhesion to a planar surface 
The ability to visualize a large number of individual bio-nanoparticles opens up 
the possibility of exploring many interesting scientific questions. Simply understanding 
the parameters of the microarray and flow cell offer interesting insight into the design of 
the experiments. We wanted to explore whether this system can be modelled as a single 
analyte (virus population) irreversibly captured on the microarray. This model will allow 
us to further explore how changing variables affects the system. To model the transport 
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and binding kinetics we will take into account convection and diffusion of the virus 
particles, as well as the reaction on the surface of the sensor. The specific chemical 
interaction between biomolecules, such as antibody-antigen, DNA-DNA, or protein-
protein, is typically governed by electrostatic interactions, hydrogen bonds, and Van Der 
Waals forces. These types of chemical interactions are often modelled with the Langmuir  
adsorption model (Equation 4) which uses forward and reverse rate constants to 
characterize the reaction. The forward rate constant kon determines the rate at which the 
components form a complex. In the particular instance of virus binding to a surface, this 
would be the reaction between the entire viruses sticking to the surface through the 
specific antibody-antigen interaction. The reverse rate constant, koff, or off rate is the rate 
at which viruses leave the surface.  However, when nanoparticle binding is considered, 
there are some key differences which can cause variations from the model. Nanoparticles, 
being 10’s to 100’s of nanometers, contain many probe molecules and are binding to a 
surface with many conjugate molecules. This creates the possibility of multiple 
interactions forming, which causes an accumulated binding strength, known as avidity. 
This is commonly referred to as function affinity. The formation of a single bond in this 
paradigm greatly increases the likelihood of additional bonds forming. Additionally, 
individual unbinding of a single bond will not allow the molecule to leave the surface, 
greatly reducing the effective off-rate.  
Although affinity constants are known for many biomolecule pairs, very little is 
known about the functional affinity of mesoscale particles and how this relates to the 
Equation 4 
 
(4) 
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kinetics of bond formation. It has been suggested that there are many variables which 
play a role in the nanoparticle attachment such as particle size, flow velocity/shear force, 
receptor and ligand densities, receptor and ligand sizes, as well as bond strength, and 
probe flexibility[31]–[33]. Additionally, it has been shown that in certain cases the 
binding does not depend on the kinetics of the antibody-antigen reaction, which is 
contrary to most theory as well as common intuition[31]. 
To begin understanding this process it is useful to remove as many variables from 
the experiment as possible. The simplest model to develop is a static model in which the 
fluid is stationary and there is no flow. In the limit where the fluid does not move, the 
Damkohler number is very large, or the reaction rate is much faster than the convection 
rate. Although the reaction rate may be an unknown for a nanoparticle system, we can be 
sure that it is dominant for most biomolecule pairs because the convection is zero. At this 
limit the particle binding rate should be minimally affected by small changes in the 
affinity because the nanoparticles should have enough time to interact with the surface 
and form a bond. In this scenario the avidity affects should minimally affect the binding 
rate of the particles, but will still reduce unbinding. 
 
5.5.1. COMSOL Model Design 
 
The simulation software, COMSOL Multiphysics 5.2, was used to develop the 
model. A three dimensional chamber was designed with the microarray of spots on the 
bottom surface. Three physics modules were used to develop this model, laminar flow, 
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transport of dilute species, and the surface reactions module. The flow in these models 
and experiments ranges from completely static to laminar. The size of the flow cell and 
ranges of flow rates that we are interested in will never transition to turbulent flow. For 
that reason we can use the laminar flow module or even the creeping flow module, which 
would further simplify the simulations but likely not impact the results. Initially I have 
decided to use the laminar flow module which utilizes the Navier-Stokes equation 
(Equation 5) and the continuity equation (Equation 6).  
These are solved for steady state incompressible flow where u is the velocity of 
the fluid, p is the pressure, ρ is the fluids density, and µ is the dynamic viscosity. The 
working fluid for this model was water at 293.15 K.  
The second physics module, transport of dilute species, considers the mass 
transport of the nanoparticles in solution. This takes into account both convective and 
diffusive mass transport. Equations 7 and 8 are used in this module, in which c is the  
Equation 5  
(5) 
Equation 6  (6) 
Equation 7  
(7) 
Equation 8  (8) 
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concentration of the species, and D is the diffusivity calculated using the Stokes-Einstein 
equation for a spherical particle at low Reynolds number (Equation 9). In  
Equation 9, Kb is the Boltzmann constant and T is the working temperature.  
The third module used is the surface reactions module. This defines the reaction 
rate occurring at the spots and depends on the surface probe density, the surface 
concentration of analytes, and number of bound analytes as well as the binding and un- 
 binding rate of the particles. In Equation 10, Rs,i is the reaction rate which is defined by 
the difference between the adsorption rate of the nanoparticles minus the desorption rate 
of the nanoparticles (Equation 11). Furthermore, the adsorption and desorption rates are 
defined using the forward and reverse rate constants for the biomolecule pair. The 
adsorption rate, Rads, is defined in Equation 12, where kon is the forward rate constant, Cp 
is the concentration of the analyte in solution at the surface, θfree is the proportion of 
unbound sites on the surface, and τs is the total surface probe density. Equation 13 shows  
the desorption rate, Rdes, of the bound nanoparticles depends on the surface concentration 
of bound particles, Csp, and the off rate of the biomolecule pair, koff.  
Model mesh and element order are important parameters to keep in mind when 
creating a numeric model in COMSOL. Both decreasing mesh size and increasing 
Equation 9 
 
(9) 
Equation 10  (10) 
Equation 11  (11) 
Equation 12  (12) 
Equation 13  (13) 
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element order have a similar effect on reducing the errors associated with numeric 
approximations. However, they also both have the result of increasing memory usage and 
solving time for the model. Choosing too fine a mesh or too high an element order will 
not create an incorrect solution, but can be prohibitive to solve. In most cases, the mesh 
and element order are reduced as much as possible while maintaining an acceptable level 
of accuracy for the given model. For this particular model we are will be looking at the 
total number of bound particles over an entire spots. This allows us to integrate the bound 
surface density across a relatively large area. This integration of the model results will 
help to reduce any numeric errors that may arise. 
COMSOL contains automatically generated, physics controlled meshes that are 
appropriate for the development of most models, but are not usually optimized for the 
specific geometry or simulations being explored. These physics controlled meshes can 
 
Figure 10:  Physics Controlled Mesh 
Figure 10 shows the coarse physics controlled mesh with a close up of the mesh on one of the reactive 
surfaces. 
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work well but are inefficient with resources, because they are usually relatively 
homogenous. Typically, it is easiest to develop a model with pre-made mesh and then 
refine or redesign the mesh once the model is working appropriately. This was the 
method used to develop this model. Initially a relatively coarse physics controlled mesh 
was used and is shown in figure 10. The circles are the reactive surface that represent the 
antibody spots where viruses will bind. This is the most interesting part of the model and 
what we are most interested in. With the physics controlled mesh, in order to refine the 
element size on the reactive surface we are forced to refine the mesh for the entire model. 
This greatly increases the memory usage and time it takes to solve with each refinement. 
This mesh was used to develop the model and do initial experimental validation, but to 
improve usability of the model and efficiency of the model mesh improvements were 
desired.  
In collaboration with Barbaros Cetin at Bilkent University, Ankara, Turkey, an 
improved mesh was designed. Figure 11 shows the user defined mesh used for this 
model. This model mesh has a finer mesh size on the reactive surface without 
unnecessarily decreasing the element size in regions that are not of interest. The reactive 
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surface has an element size limit ranging from 1-10 µm, where as the remainder of the 
model has an element size ranging from 15-62 µm. This helps to improve the accuraccy 
of the model without undo burden on the computational cost. Additionally, due to the 
high aspect ratio of the geometry, the thin dimension was allowed to have a finer element 
size as well.   
Figure 12 shows the effect of mesh refinement on the total number of particles 
bound in a simulated experiment. The y-axis is the total number of bound particles after 
integrating the surface concentration over all the spots. Using the custom defined mesh, 
the element size of the reactive surfaces (the antibody spots) was continuously refined. 
With each refinement the total number of bound particles for all the spots was calculated. 
This was then plotted against the number of degrees of freedom solved for. Figure 12 
shows the model rather quickly converges without significant variation among any of the 
 
Figure 11:  Custom Mesh 
Figure 11 shows the custom mesh created which provides smaller element size on the important features.  
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element sizes tested. This is not surprising due to the large area that is being integrated to 
obtain the results. By integrating over an area, we are able to minimize the numerical 
error in the simulation.  The slight overshoot of the model is likely due the still rather 
course triangular mesh approximating the circular antibody spots. Furthermore, the 
amount of processing time required to increase the accuracy of the model is fairly 
minimal thanks to the efficiency of the defined mesh. This demonstrates the importance 
of defining a mesh appropriately for a given model.   
Beyond mesh considerations, there is also the matter of discretization, or element 
order. Each element within the model has a shape function associated with it, and the 
shape functions are associated with some degrees of freedom. First order, or linear, 
element orders are often appropriate for a single phyisics module assuming a sufficient 
mesh refinement has already occurred. Certain physics, or multiple physics packages 
 
Figure 12: Mesh Refinement 
Figure 12 shows the change in total number of bound particles for the different meshes tested 
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combined can require higher order elements to achieve reliable results. Once the mesh 
refinement was tested and the custom mesh created, higher order elements were tested. 
For the flow module, a discretization setting of P3 + P2 was tested. This means the 
velocity field used a cubic, or third order, element, and the pressure field used a 
quadratic, or second order element.  The transport of dilute species module used a 
quadratic element for the concentration field. The surface reaction module used quadratic 
elements to solve for the surface concentration and the bulk concentration.  
When using the higher order elements, the number of degrees of freedom 
increased dramatically. Additionally the memory required to solve the model required the 
use of a super computer and took over an order of magnitude more time to solve without 
improving the accuracy of the model. For this model the mesh refinement is a more 
efficient method of converging on a solution than using a higher order element. It should 
be noted that for the purposes of this model even a deviation from experimental results of 
10% woud be deemed sufficient.  
 
5.5.2. Experimental Validation of Model 
To test this model we created a static incubation chamber that was made with 
stacked polymer-PSA laminates allowing us to adjust the height of the channel by adding 
or removing layers. The layers were bonded together and cut using a GRAPHTEC craft 
ROBO cutter, which resulted is smooth and clean edges. Figure 13 shows the incubation 
chamber made from stacked laminates on the left. The tabs on the corners aid in bonding 
and removal of the incubation chamber from the chip. The middle of figure 13 shows the 
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10mm x 10mm IRIS chip which was used for the initial validation experiments. The right 
side of figure 13 shows the incubation chamber adhered to the chip. Once the incubation 
chamber was adhered to the surface of the chip, it was filled with ~5 µL of sample and 
sealed with an additional polymer laminate film. This was then allowed to incubate 
before the chamber was removed, the sample was thoroughly washed and the chip dried. 
The dried chip was then scanned using the automated nanoview instrument to count the 
number of bound particles.  
The nanoparticles used for the experiments were 100 nm polystyrene beads 
functionalized with biotin. The microarray consisted of a 3 by 3 array of streptavidin 
spots printed with the Scienion SciFlex Arrayer. Each spot was roughly 150 µm in 
diameter and 900 µm apart. To match this experimental incubation chamber a 3 
dimensional model, shown in Figure 14, was built in COMSOL which had 400 µm high 
 
Figure 13:  Static Incubation Chamber 
Figure 13 shows the stacked PSA static incubation chamber, as well as the IRIS chip with and without the 
attached chamber (unsealed). 
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walls and 4 mm x 4 mm side dimensions. The circles shown in figure 14 are the antibody 
spots on the bottom surface of the sensor.   
Table 5: Model Parameters 
Variable Expression Description 
D kb*293.15*(6*(1.002e-3)*3.1415*r)^-1[K*Pa^-1*s^-1] Diffusion Constant 
u_in 0.00[m/s] Inlet velocity 
c0 1.67e-14[mol/L] Molar concentration 
kb 1.3806e-23 [m^2 * kg * s^-2 *K^-1] Boltzmann constant 
r 50[nm] Particle radius 
probe 5e-4[mol/m^2] Surface probe density 
kon 5e8[L/(mol*s)] Kon value 
koff 1e-6 [1/s] Koff value 
kd koff/kon Dissociation constant 
pitch 900[um] Spot pitch 
height 500[um] Channel height 
spotsize 150[um] Spot diameter 
 
 
Figure 14: COMSOL Model of Static Incubation 
Figure 14 shows the COMSOL geometry used for the static incubation chamber. 
  
51 
By developing the model using COMSOL we were able to easily change variables 
for different experimental conditions, which makes it a more broadly applicable model as 
well as easier to validate. Parameters for this simulation are shown in table 5.  
 
Table 6: Experimental Values 
Particles/Sample Particles/ml Moles Molarity 
502,400 108 100 zM 100 fM 
50,240 107 10 zM 10 fM 
25,120 5 x 106 5 zM 5 fM 
5,024 106 1 zM 1 fM 
2,512 5 x 106 .5 zM .5 fM 
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Figure 15: Experimental and Theoretical Dilution Curve in Static Chamber 
Figure 15 shows an experimental dilution curve using 100nm polystyrene particles conjugated with biotin at 
different concentrations, as well as the COMSOL model prediction for the same experiment 
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The first experiments and simulations were run with the parameters shown in 
table 5 for 16 hours using varying initial concentrations of nanoparticles. The average 
number of particles per sample was calculated and shown in Table 6 along with the 
conversion between particles per mL, Moles per sample, and Molar concentration.   The 
number of particles per sample was then plotted against the total number of particles in 
the sample on a log-log plot in Figure 15.  The experimental results are plotted as black 
dots and the COMSOL simulation was plotted as black X’s. A best fit line was added to 
the simulation data points to show the expected linear trend. The experimental results 
show very good correlation with the theoretical predictions with reasonable experimental 
variability.  
 
Figure 14: COMSOL Model of Static Incubation Chamber  
Figure 14 shows the COMSOL geometry used for the static incubation chamber. 
 
 
Figure 14: COMSOL Model of Static Incubation Chamber  
Figure 14 shows the COMSOL geometry used for the static incubation chamber. 
 
Figure 16: Surface Concentration Plot  
Surface concentration simulation of the bulk fluid concentration at the sensor surface after 16 hours of 
incubation with a starting sample concentration of 1x107 particles/mL. 
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The spot spacing of 900 µm was chosen arbitrarily but sensor spacing is an 
important parameter that can be further explored using this model. Efficient use of the 
sensor surface needs to be balanced with sample depletion interfering with neighboring 
spots. The model shows that the sample depletion does spread outward significantly from 
the spots as is expected. Figure 16 shows how spots spaced at 900 µm still have the 
potential for sample depletion to impact neighboring spots.  
The model suggested that spot pitch needed to be further explored both 
experimentally and theoretically. To do this, a four by 4 grid of spots was arrayed at 
differing spacing on sensors and incubated in a 400 µm high chamber shown in Figure 9 
for 16 hours.  Spot pitches of 300, 400, 600, 700, 800 and 900 µm were tested. The 
average number of particles bound to the 4 spots in the center of the array was used to 
reduce variability caused by the location of the spot in the grid. These incubations 
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Figure 17: Spot Pitch Binding Plot 6 
The experimental results and the COMSOL simulation of the average number of bound particles at different 
spot pitches after 16 hours of incubation with a starting sample concentration of 1x107 particles/mL. 
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occurred with an initial sample concentration of 1x107 particles/mL. Figure 17 shows the 
average number of particles bound on the spots with experimental results shown as blue 
dots and COMSOL simulation results plotted with blue X’s. As the spot pitch increases 
the number of bound particles increases in both the experimental and theoretical data. 
The experimental data is similar to the number of particles predicted by the simulation; 
however, the data varies a bit. The experimental data shows a nearly linear trend, whereas 
the simulation predicts more of an asymptotic trend in which the benefit gained from 
increasing spot pitch is reduced as the spot pitch grows larger and larger. From the data 
shown the variation is likely just normal experimental variability. Extending the 
experimental results to larger spot pitches would help elucidate any differences between 
the model and the experimental data, but the spot pitch is limited by the size of the sensor 
and chamber width, therefore larger spot spacing becomes unrealistic.  
It becomes clear that spot pitch, chamber height, and time all affect the number of 
bound particles. However it is easier to explore the variables separately while considering 
how they might effect on another. For example, the Einstein diffusion approximation, 
Equation 14, can be used to estimate the time it takes for a particle to diffuse a certain  
distance, or the distance a particle might diffuse given a certain amount of time.  We can 
see from this equation that given 16 hours a 100nm particle in water has mean distance 
travelled of approximately 500 µm. Therefore, for a 16 hour experiment, a spot pitch 
significantly less than 1000 µm will likely cause depletion interference between 
neighboring spots. Additionally, a chamber height significantly thinner would reduce 
Equation 14 
 
(14) 
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binding, whereas a thicker chamber would offer little benefit as the sensor would not be 
effectively probing that solution.  
To expand on this knowledge and further validate the model, a set of experiments 
were performed in which a 900 µm spot pitch was used with chambers that were 100, 
200, and 400 µm thick. These experiments were repeated for 12 hours, 16 hours, and 20 
hours to explore the variable space and look at the impact of the incubation time on 
binding. Figure 18 shows both the experimental results, and the COMSOL simulation for 
this scenario. The experimental results showed a consistent ~20% variation from the 
theoretical prediction across nearly all of the chamber thicknesses and time points. This 
suggested that the sample concentration might have been slightly different than what was 
reported. Regardless of the slight experimental error, the experimental results and 
simulation agreed very well on the trends of the data. The thicker chambers consistently 
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Figure 18: Chamber height and Time  
The experimental results and the COMSOL simulation of the average number of bound particles when 
incubated in chambers of varying height for 12, 16, and 20 hours at 1x107 particles/mL. 
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produced greater binding for all time points. This is expected because for all the time 
points tested, the mean distance diffused by a particle is greater than the channel height. 
In other words, by increasing the chamber thickness the sensor is allowed to probe a 
greater volume of solution, resulting in more bound nanoparticles. The thinner chambers 
would actually restrict the volume that each spot ‘sees’. Furthermore, for the 
experimental times tested the results show a nearly linear increase in binding with respect 
to time. As can be seen in Figure 18, the slope of the lines is slightly greater with the 
thicker channels. This is due to the chamber heights restricting the volume that the 
sensors are able to interrogate in the z-dimension.  The thicker chambers are less 
restricted and therefore show a greater increase in binding with respect to time. Given 
enough time, one would expect the curves to level off as the sample began to be depleted.  
Alternatively, if we set the experimental time due to a realistic restraint, such as a 
16 hour overnight experiment. We can see if there is an optimal chamber thickness for 
this length experiment. By using the COMSOL model we can simulate the expected 
number of particles bound for 16 hour incubation with a 900µm spot pitch in incubation 
chambers of varying thicknesses. Figure 19 shows the simulation results for chambers 
that are 100, 200, 400, 600, and 800 µm thick incubated for 16 hours with a nanoparticle 
concentration of 1x107 particles/mL. The simulation shows that increasing the chamber 
height initially gives a significant increase in the number of bound particles but as the 
chamber gets thicker and thicker the benefits gained are reduced. A 400µm chamber 
shows significantly more binding than either a 100 or 200 µm chambers, but the 600 or 
800 µm chambers show just marginally more bound nanoparticles than the 400 µm 
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chamber. This can be easily understood by looking at Equation 13. We see that a 100nm 
particle in water at room temperature has a mean distance travelled of just under 500 µm 
due to diffusion. Therefore making the chamber thickness larger than that will have 
marginal benefits because it is unlikely that particles at that distance will diffuse to the 
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Figure 19: Simulation of Chamber Thickness  
COMSOL simulation of the average number of bound particles when incubated in chambers of varying 
height for 16 hours at 1x107 particles/mL. 
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sensor surface to be captured. For a static chamber with an experimental time of 16 hours 
we see that a spot pitch of 900 µm with a chamber thickness of 400 µm will give optimal 
performance for 100nm particles in water.  
The model developed for a static chamber proved to be quite accurate and useful 
for optimizing an incubation chamber. However, the next step in the model is introducing 
flow. The question remains how a flow cell can be optimized using this model.  The 
Laminar Flow COMSOL module was used to develop the static model as well with an 
inlet velocity set to zero. To change this model to accurately depict the flow cells, the 
model geometry first needed to be changed. The channel height was set to 25 µm and the 
channel width was set to 2000 µm. This matched the cartridge that was tested. The 
geometry is shown in Figure 20, with the length of the channel being set to 4mm with 13 
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Figure : Simulation of Chamber Thickness  
Figure 19 shows the COMSOL simulation of the average number of bound particles when incubated in 
chambers of varying height for 16 hours at 1x107 particles/mL. 
 
 
ig re 20: Slice Plot of Velocity Profile 
COMSOL geometry used for modelling the binding of nanoparticles under flow conditions. 
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spots aligned with the flow going down the middle of the channel. Each spot is 
approximately 150 µm in diameter and spaced 288 µm apart as is done in the 
experimental preparation.  
First, the Laminar Flow module was solved for using a stationary study with a 
volumetric flow rate of 10 µL/min, which corresponds to an inlet velocity of 3.3mm/s.  
This creates the typical parabolic planar Poiseulle flow profile that is expected with a 
parallel plate flow chamber with an aspect ratio of ~1/100. Figure21 shows the velocity 
flow profile from the COMSOL simulation which matches with the expected analytical 
solution for planar Poiseulle flow. Using 100nm polystyrene particles functionalized with 
biotin, at a concentration of 1x107 particles/mL, the flow cell was incubated for one hour.  
Figure 21 shows the COMSOL simulation of the sample depletion that occurs 
along the direction of flow, down the length of the channel. The red indicates the bulk 
sample concentration and the direction of flow is from left to right. The first spot in the 
 
Figure 21: Concentration Surface Plot 
COMSOL simulation of the bulk fluid analyte concentration at the surface of the sensor. 
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channel essentially experiences the bulk sample concentration. Figure 23 shows the 
experimental results plotted as black circles in which the x –axis is the position of the 
spot from the entrance of the flow cell. The number of particles bound to each spot is 
decreased as the distance from the entrance increases. This occurs because the first spot 
binds some of the nanoparticles in solution which effectively reduces the concentration 
that the following spot sees. This is a prime example of sample depletion and occurs for 
each subsequent spot. The functional affinity used for the 100nm particles under a wall 
shear flow of 800 1/s is 5x104 1/M*s. This represents a function affinity ~3 orders of 
magnitude lower than the commonly accepted kinetic on rate for free biotin and 
streptavidin. 
 Under the flow conditions convection is a much stronger aspect that needs to be 
considered which means the reaction rate also plays a stronger role in this scenario. 
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Figure 22: Particles per Spot along Channel 
Experimental results of number of particles bound to each spot plotted against the positon of the spot from 
the entrance of the flow cell. The COMSOL simulation is plotted as X’s.  
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Traditional theory suggests that small changes in the forward reaction rate, determined by 
the rate constant kon, will dramatically impact the binding rate. However research 
conducted on nanoparticle binding has shown that the value for kon does not always 
impact the nanoparticle adhesion dynamics in the way molecular binding properties 
would predict[31]. The research conducted by Jered B. Haun, et al. includes binding 
curves of 210nm particles functionalized with biotin binding to a neutravidin surface. 
However, when the parallel plate flow chamber they used was modelled with the same 
experimental conditions and reported kinetic rates, the results vary from the data 
presented[31], [34]. However if the kinetic value, kon, is reduced by ~2 orders of 
magnitude to represent the functional affinity of the molecular interaction when 
combined with a nanoparticle, the model then matches the experimental values. This 
suggests that nanoparticle attachment rates under flow conditions can vary significantly 
from what the molecular binding properties predict. This agrees with the concept of 
functional affinity, which as of yet is poorly understood and poorly predicted.  
 
 
6. CHAPTER SIX: CAPILLARY DRIVEN CARTRIDGE DESIGN 
Dependence on a syringe pump greatly restricts the usability of this cartridge at 
the point-of-care, where rapid results are most useful. The sixth chapter deals with 
overcoming this, by utilizing a capillary driven microfluidic cartridge that can maintain 
flow for an extended period with a complex sample. We have shown the strong time 
dependence of time on the virus capture, and the ability to run an experiment with a 
controlled flow rate for relatively long periods of time is essential to the success of the 
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assay. Lastly the ability to run a complex sample, such as serum, in the cartridge with 
minimal sample preparation represents the ideal use scenario.  
6.1. Flow Rate Optimization 
 Aside from the obvious advantages of a microfluidic flow cell, such as smaller 
sample volume, the miniaturized design offers benefits of increased surface area to 
volume ratio and improved mass transport[35]. Most micro well plate based assays are 
diffusion limited and thus the reaction often takes hours to reach completion. Studies 
have shown that conducting this reaction in a flow cell can increase the binding rate by 
increasing the proximity of the capture molecule to the sensor and constantly replenishing 
any sample depletion[36]. 
 Under normal flow conditions in a flow cell, particles move past the sensor more 
quickly than they can diffuse to the surface, as would be the case for moderately fast 
flow, and only particles very close to the sensor surface in the depletion zone will be 
captured. A common method of modeling the impact of flow is by assuming 
instantaneous reaction and examining the flux of particles through the depletion zone. 
One can estimate how changing parameters such as flow rate, channel height, or channel 
width will impact the binding rate[35]. The expected dependence is: 
 Where the width (W) is restricted by the number of spots in the microarray we want to fit 
in the channel. The height (H) is limited by commercial availability of polymer 
laminates, and thus 0.001 in (25.4µm) is the thinnest we can reasonably make our 
channel. However an increase in flow rate (Q) should correlate with a modest increase in 
Equation 15  (15) 
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the flux of particles (F) and therefore binding rate. This model suggests there is no upper 
limit on the flow rate, and increasing the flow rate should continuously increase the 
binding. However, the model suggests nanoparticle functional affinities are much lower 
than the molecular affinities. Therefore the assumption of instantaneous binding is 
probably not valid. To get a better idea of how the flow rate might affect the binding, we 
can vary the flow rate using the COMSOL model for a number of functional affinities in 
the range of what was seen for previous experiments. Figure 23 shows the normalized 
number of bound particles at flow rates ranging 8 orders of magnitude for a functional 
affinity of 5 x 103 1/Mol*s, 5 x 104 1/Mol*s, and 5 x 105 1/Mol*s. Each of these curves 
produced a different total number of bound particles per flow rate, but showed the same 
asymptotic shaped curve. The number of bound particles for each curve was normalized 
to the number of particles that was bound at the highest flow rate. This helps us look at 
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Figure 23: Flow Rate Impact at Different Functional Affinity 
The effect of flow rate on binding at different functional affinities 
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the relative change inbound particles with respect to flow rate. Figure 24 shows us 
several interesting points. First, the binding does not continuously increase with increased 
flow rate, but levels off at high flow rates. This suggests there may be an optimal flow 
rate for a given functional affinity. It should be noted however that the functional affinity 
may depend on the flow rate, and this model does not use a dynamic functional affinity 
that is affected by flow rate. The obvious hypothesis is that the functional affinity would 
decreases with increased shear rate (α flow rate), and these curves would likely level off 
and potentially begin decreasing. Second, at the low functional affinity, we see only ~5 
fold increase in bound particles over the entire range of flow rates tested. This is in 
contrast to the simple model mentioned above.  
To test the effect of flow rate, a syringe pump was used to deliver sample to the 
incubation cartridge at a controlled rate. In order to determine the optimal flow rate, a 
 
Figure 24: Flow Rate Optimization 
Effect of flow rate on virus capture reported as viruses/mm2. Increasing flow rate increases virus capture and 
reducing flow (or stopping flow) decreased capture rate.  
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sample was prepared of PBS with 1% BSA spiked with 5x103 PFU/mL rVSV-ZEBOV. 
This sample was driven through the cartridge with a syringe pump at flow rates of 0, 0.1, 
1, and 10μL/min. Each flow rate was maintained for 15 minutes before changing to the 
next flow rate sequentially in a single experiment. The results of this experiment are seen 
in Figure 24. The blue line in figure 24 is the number of viruses bound at a flow rate of 0 
µL/min, or no flow. The flow rate was then increased to 0.1 µL/min and shown in red, 
followed by 1 µL/min shown in green and finally 10 µL/min in purple. This experiment 
was repeated both increasing the flow rate from 0.1-10μL/min as well as decreasing from 
10-0.1μL/min with the same trend apparent in both scenarios. The binding rate, in viruses 
captured per minute, was normalized to the area of the spot and reported for the different 
flow rates in figure 24. Again the colors correspond to the flow rates shown in figure 25 
as well. This shows a modest increase in binding rate with increased flow rate as 
 
Figure 25: Flow Rate Optimization 
Normalized binding rate in viruses/minute/mm2.  
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predicted by the flux equation. The difference in binding rate between 1 and 10μL/min is 
insignificant and the reduced sample volume required by flowing at the slower 1μL/min 
makes this flow rate optimal for the assay. 
 
6.2. Development of Capillary Driven Flow Cartridge 
According to the World Health Organization (WHO) an ideal POC test should 
follow the ASSURED criteria: affordable, sensitive, specific, user-friendly, robust and 
rapid (<30min), equipment free or minimal equipment, and deliverable[1]. Typically 
paper based assays are used to meet these criteria, but these often lack in sensitivity and 
are difficult to implement robust fluid control or multiplexed testing [37] [38]. In order to  
meet these criteria a cartridge was designed for IRIS to have a similar work flow to a 
paper based lateral flow assay with an automated reader. The capability of paper to 
passively transport fluids via capillary forces is an attribute we chose to take advantage 
of. By incorporating paper-based fluid handling we were able to reduce the need for 
external equipment. 
To achieve a steady controlled flow rate at ~1µL/min for at least 30 minutes a 
rectangular absorbent pad will not suffice. As described by the Lucas-Washburn equation 
(equation 16) the flow rate decreases with length, given a constant width. To overcome 
this, a single layer absorbent pad with a 270 degree fan shape was placed in the channel 
after the sensor[39]. Using this shape, shown in figure 26, the stem width and length can 
be experimentally varied to control the flow rate. In this phase, the flow rate decreases as 
Equation 16 
 
(16) 
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it wicks down the length of the pad. Once the fluid front reaches the circular region in 
phase 2, the increasing perimeter of the advancing flow front increases the driving force 
at approximately the same rate as the fluidic resistance increases, maintaining a quasi-
steady flow rate.  By combining the two phases we can develop a theoretical model for  
the time it takes to saturate the pad (equation 17). This equation tells us what variables 
the system depends on and how we expect them to affect the resultant flow. 
Unfortunately, many of the intrinsic properties of the pad are unknown and an analytical 
solution is not possible.  
Equation 17 
 
(17) 
 
 
Figure 26: Capillary Driven Cartridge Design 
The fan shaped absorbent pad with the fluid path used in the passive flow disposable cartridge on the right. 
The fluid flow properties can be separated into two distinct phases as shown above. 
Phase 1 Phase 2
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However, empirical analysis of the fluid front moving across the pad shows that 
the designed pad shape does in fact maintain a quasi-steady flow rate. A 100 µL sample 
was placed in the reservoir and the fluid was pushed into the channel by screwing a luer 
cap onto the reservoir, thereby displacing air. Once the fluid contacted the absorbing pad, 
the material continued to wick the sample into the pad at a quasi-steady rate. This 
continued to draw fresh sample over the sensor without the need for external fluid 
actuation giving a repeatable incubation of the sensor. In order to measure the flow rate, 
images were taken every 30 seconds. The wetted region (shown in red in Figure 27A) 
was calculated as a percent of the total pad area (shown in blue in Figure 27A). The 
percent of wetted area was then multiplied by the total volume absorbed during the 
experiment to determine the flow rate at each time interval. Analysis of the fluid front 
moving across the pad showed that the designed pad shape did in fact maintain a quasi-
steady flow rate of ~3 µL/min for approximately 20 minutes, as shown in Figure 27. This 
 
Figure 27: Capillary pad flow rate measurement 
Passive pad flow rate was measured by measuring the wetted region of the pad at different points throughout 
the course of saturation. The red indicates where the pad is wet. 
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satisfied the requirements of maintaining a flow rate in the range of 1-10 µL/min for 
approximately 20 minutes, while using a sample volume of 100 µL or less.  
Figure 27 shows that by measuring the diameter of the pad and the diameter of the 
wetted region, and knowing the maximum saturated volume of the pad, the flow rate can 
be approximated over the course of an experiment. This simple method shows that the 
flow rate remains fairly constant throughout the course of the pad saturation. By simply 
adjusting the length of the straight portion of the pad, we were able to adjust the nominal 
flow rate to within the range suggested by figure 25. Furthermore, when the pad is fully 
saturate the flow will slowly stop, which ensures the sensor will never dry out.  
The final cartridge design incorporates this 2-D paper based capillary driven flow 
into the multilayer polymer laminate cartridge as shown in Figure 29B[40]. This design 
was produced using a scalable manufacturing process that promises a low cost device at 
high volumes. The final design has a sample reservoir, 3-dimensional fluidic network 
exposing the surface of the sensor to the sample, an optical imaging window, and 
capillary driven flow which also acts as waste reservoir containing the sample completely 
 
Figure 28: Syringe Pump and Capillary Driven Flow Cartridge 
The disposable syringe pump drive cartridge and B) the passive cartridge with integrated paperfluidic flow 
control and imaging window. 
  
70 
within the cartridge. This represents a significant improvement over the previous design 
shown in Figure 28A[41]. The previous version of the cartridge was connected to tubing 
and flow was controlled via a syringe pump. This would have been a significant burden 
on the user and would require additional infrastructure and cost to operate the system. 
6.3. Capillary Driven Cartridge Repeatability with Serum 
Having established that the capillary driven cartridge design can continuously 
draw fluid across the sensor for an extended period of time, we began validating the 
repeatability of the cartridge. Ten cartridges were prepared by spotting anti-Ebola, anti-
Lassa and anti-Marburg antibodies on the sensor. First, five of the cartridges were tested 
using 100 µL of FBS spiked with rVSV-ZEBOV at a final concentration at 1 x 104 
PFU/mL. The cartridge was actuated and the full array was scanned every 25 minutes for 
the first 100 minutes. Then the array was scanned at 150 and 200 minutes to gather 
further time points.  
Figure 29 shows the average of the individual spots on a single sensor with error 
bars representing the variation between spots within a cartridge. The blue data points are 
the anti-Ebola 13F6 antibody and show increasing virus capture reported as virus density. 
The data points represent the average virus surface density among three different 
antibody spots in the microarray. The error bars show that there was fairly small variation 
in the capture efficiency between the spots. The first data point at 25 minutes shows the 
most rapid capture of virus. This can be explained by the flow from the cartridge. The 
flow was designed to last for approximately 25 minutes, at which point the flow will slow 
down and eventually stop. As was shown earlier in figure 25, the flow rate has a 
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moderate effect on virus binding. The virus is expected to bind more readily under flow, 
because there will be a less significant impact due to sample depletion. Figure 30 shows 
the additional two antibodies, anti-Marburg and anti-Lassa. These both showed 
essentially no increase in virus binding during the duration of the experiment. There are 
frequently small particulates or protein aggregates on the anti-body spot created during 
printing of the microarray. These can be on the same order as the size of the virus. Due to 
this the negative spots may not be exactly at zero particles, but the time points show no 
accumulation of viruses during the experiment. This gives confidence that the particles 
captured on the anti-Ebola antibody are in fact viruses and the test worked correctly.  
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Figure 29: Ebola Intracartridge Repeatability of Capillary Driven Cartridge 
The intracartridge variability of a single capillary driven cartridge with pseudotyped rVSV-ZEBOV 
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Figure 30 shows the analogous results to figure 29 showing the capture of the 
pseudotyped rVSV-LASV. These results show a similar trend with the green data points 
representing the anti-Lassa antibody. The most rapid binding again occurs in the first 25 
minutes where the flow of the sample is most prevalent. Additionally, the interspot virus 
capture variability is relatively low. The anti-Ebola and anti-Marburg antibodies show no 
virus accumulation during the experiment which suggests the experiment worked 
appropriately and the viruses are only binding to the anti-Lassa antibody. It can be noted 
that the ant-Ebola and anti-Marburg viruses are not at exactly zero, which again is due to 
nano-particulate or protein aggregates present during chip printing. The dynamic 
measurements however give good confidence that the detected particles are not viruses, 
because they show no increase when exposed to the sample during the entire experiment.  
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Figure 30: Lassa Intracartridge Repeatability of Capillary Driven Cartridge 
Intracartridge variability of a single capillary driven cartridge with pseudotyped rVSV-LASV  
-LASV 
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 Figure 31 shows the average values across five different cartridges at time points 
from 25 minutes to 100 minutes. The blue data points are the values for the pseudotyped 
rVSV-ZEBOV. The error bars indicate that there is very little variability between 
cartridges at 25 minutes, and relatively low variability all the way up to 100 minutes. 
This is very important because the test needs to be consistent from one cartridge to 
another to maintain semi-quantitative results. The red and green data points are the anti-
Marburg and anti-Lassa antibodies respectively. Again, the tests showed very good 
specificity between cartridges with little non-specific binding detected. Additionally, the 
plot shows that the majority of the binding occurs within the first 25 minutes when flow 
is active among all cartridges further supporting the previous data for the effect of flow 
on capture of viruses.  
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Figure 31: Ebola Inter-Cartridge Variability of Capillary Driven Cartridge 
Intercartridge variability of five capillary driven cartridge with pseudotyped rVSV-ZEBOV 
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Figure 32 shows the data for the average of the five cartridges which were tested 
with rVSV-LASV samples. These data points were again taken at 25 minute intervals up 
to 100 minutes. The error bars are used to show the variability between the cartridges, 
which again is relatively low. This low variabiltiy is a positive result showing the 
cartrdiges are very repeatable from one to the next. The green data points represent the 
virus capture on the anti-Lassa antibody, which shows the same trend of acccumuation as 
seen on the previous test with anti-Ebola in figure 31. The red and blue data points show 
the virus capture on the anti-Marbur and anti-Ebola antibody spots, which again show 
very little non-specific binding or accumulation of viruses. 
The disposable cartridge demonstrates a consistent flow rate and repeatable test 
results both between the spots within a single cartridge, as well as between different 
cartridges. This shows that the paper based capillary flow control can be used in place of 
an external instrument, such as a syringe pump, to improve the usability of the test. 
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Figure 32: Lassa Inter-Cartridge Variability of Capillary Driven Cartridge 
Intercartridge variability of five capillary driven cartridge with pseudotyped rVSV-ZEBOV 
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Having repeatable test results with minimal user input is extremely important to create a 
semi-quantitative test that can be used in different labs and settings, while producing 
comparable results. It is also important that the test can be used in a multiplexed format 
with the ability to detect multiple different viruses or nanoparticles, which demonstrates 
the capability of this as a platform for virus and nanoparticle detection.  It should be 
noted that the sensor remains legible for significantly longer and is still usable after 24 
hours.   
6.4. Capillary Driven Cartridge Sensitivity with Serum 
Having shown the capillary driven flow cartridge was optimized for flow, it was 
necessary to determine the performance and sensitivity of the system. We have shown 
that the syringe pump driven cartridge was capable of sensitive detection of individual 
virus particles directly from serum[41]. We have also shown that the capillary driven 
cartridge is capable of repeatable results with multiple different virus samples. To 
determine the system performance we conducted a dilution experiment using rVSV-
ZEBOV spiked into 100% fetal bovine serum (FBS). Serial dilutions were prepared from 
the stock sample of rVSV-ZEBOV at 1:5, 1:50, 1:500, and 1:5000 fold dilutions in FBS. 
The disposable cartridges were assembled with the sensor chip containing 4 spots each of 
anti-Ebola antibody (13F6), anti-Marburg antibody (74-1), anti-Lassa antibody (8.9F), 
and a negative control antibody (8G5) for wild type VSV-G, which should not be present 
in the sample. A 100 µL sample was pipetted into the sample reservoir of the disposable 
cartridge. The cartridge was then activated by screwing the cap on and immediately 
inserted into the automated reader. The test was allowed to run for a total of 20 minutes 
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with each spot being scanned once every 2 minutes. The three best quality spots 
(determined prior to the experiment) of the four antibody spots for each condition were 
scanned during the experiment for a total of 12 individual spots being monitored during 
the experiment.  
 Figure 33 shows the results of the highest concentration sample tested in the 
dilution sensitivity experiment. Each data point represents the average number of viruses 
the automated software detected on the three spots scanned of each antibody.  The orange 
data points in figure 34 show the number of viruses detected on the anti-Ebola antibody, 
which shows continuous accumulation during the experiment. The other data points, 
which are anti-Marburg, anti-Lassa, and anti-VSV antibodies all show no significant 
 
Figure 33: High Concentration Multiplex Detection 
The highest concentration tested in the sensitivity dilution experiments 
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accumulation. This suggested very little cross-reactivity and good specificity even at 
relatively high viral titers.  
Figure 34 shows just the anti-Ebola antibody for the 5 different samples tested, 
ranging from a 1:5-fold dilution of the stock sample to a 1:5000-fold dilution, as well as a 
blank sample that contained no virus. The highest concentration shown in blue on Figure 
34 corresponds to the orange data points on Figure 33. As expected each subsequent 
dilution showed a reduction in binding. All of the concentrations tested in this experiment 
showed a positive detection, with the lowest concentration being just above the limit of 
quantitation, defined here as the mean of the blank sample plus three times the standard 
deviation of the blank sample[42].  
 
Figure 34: Sensitivity of Capillary Driven Cartridge 
Full dilution of the sensitivity experiment for the capillary driven cartridge.  
 
 
Figure 35: Sensitivity of Capillary Driven Cartridge 
Figure 35 shows the full dilution of the sensitivity experiment for the capillary driven cartridge.  
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6.5. Comparison of Virus Detection Techniques 
In order to further validate the capillary driven cartridge test, the serial dilution 
samples tested (figure 35) were also tested using other common laboratory virus detection 
methods. The samples were divided into 4 separate aliquots, with one aliquot being used 
for IRIS, and the others being used for verification by ELISA, plaque assay, and PCR. 
Figure 36 shows the total average number of viruses detected per spot using the IRIS 
disposable cartridge for each sample in the serial dilution, including the blank sample. 
The circle data points represent the number of viruses counted on the anti-Ebola antibody 
at the end of the 20 minute experiment. The square data points represent the number of 
viruses counted on the anti-Lassa antibody at the end of the experiment. The anti-Lassa 
 
Figure 35: Comparison of Technique Sensitivity- IRIS 
The full dilution of the sensitivity experiment for the capillary driven cartridge.  
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antibody was shown to act as a negative control and further demonstrate the specificity of 
this test. The dotted line represents the limit of quantitation for this test, previously 
defined as the number of viruses detected for a blank sample plus three standard 
deviations of that measurement. This line falls below the lowest concentration but above 
all of the values recorded for the anti-Lassa antibody. The data points shown in red are 
above the limit of quantitation and were considered a positive detection. The data points 
shown in blue fall below that limit and would be recorded as a negative result. The anti-
Lassa antibody shows between zero and four viruses detected at various concentrations, 
which correlated well with the blank sample of the anti-Ebola antibody that shows a false 
detection of 3 viruses. 
 
Figure 36: Comparison of Technique Sensitivity- ELISA 
Sensitivity experiment for the sample tested using ELISA. Experiment conducted by Erik Carter.  
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Figure 36 shows the results of the confirmation of the sample using ELISA. For 
the ELISA test, the same detection antibody, 13F6, was used as in the IRIS cartridge. For 
this test, half order dilutions were made from each sample to represent the data in the 
typical fashion for ELISA results. Again in this test the circular data points represent the 
relative fluorescent units recorded by the ELISA plate reader. The data points in red 
represent positive detection of the presence of viral proteins, and the blue data points 
represent negative detection for the virus.  
Figure 37 shows the results of the plaque assay on the serial dilution samples. 
Plaque assay is a quantitative measurement and highly sensitive. This measurement 
technique shows good linearity among the samples tested and all of the samples returned 
 
Figure 37: Comparison of Technique Sensitivity- Plaque Assay 
The sensitivity experiment for the sample tested using Plaque Assay. Experiment conducted by Erik Carter.  
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a positive result for the detection of virus, hence they are all colored red. Plaque assay is 
the gold standard for virus quantification techniques, but is not a rapid test and requires 
significant laboratory infrastructure.  
The final technique tested was quantitative PCR. PCR is the most sensitive of the 
virus detection techniques available, but also often requires significant infrastructure and 
training. The results presented here in figure 38 report the number of cycles required for 
detection of each sample. Hence the increasing number of cycles required for more dilute 
samples of the virus. PCR shows positive detection of viral RNA in all samples tested as 
well.   
 
Figure 38: Comparison of Technique Sensitivity- PCR 
The sensitivity experiment for the sample tested using PCR. Experiment conducted by Erik Carter.  
 
 
 
Figure 39: Comparison of Technique Sensitivity- PCR 
Figure 39 shows the sensitivity experiment for the sample tested using PCR. Experiment conducted by Erik 
Carter.  
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Table 7 lists the values recorded for each of the detection techniques tested here. 
The values in Table 7 shown in red were considered to be positive detection of virus, 
whereas values in blue were considered negative results. The disposable cartridge, plaque 
assay, and PCR all showed correct identification of samples containing virus and the 
blank sample. However, the ELISA showed a lower detection sensitivity producing false 
negative results for the two lowest concentration samples tested. Additionally the 
disposable cartridge showed no false positives with the additional antibodies supporting 
multiplex capability.  
6.6. Comparison to Rapid Diagnostic Test 
The only blood based rapid diagnostic test currently available for Ebola is the 
Corgenix ReEbov Rapid Antigen Test, which is a lateral flow assay. This singleplex test 
for Ebola detects the presence of the VP40 matrix protein and therefore requires a sample 
additive to rupture the viral capsid prior to testing. The IRIS test captures intact virions 
through specific interactions with the surface glycoprotein (GP) on the viral envelope. 
Both the VP40 protein and GP confer the presence of Ebola specifically; however, VP40 
Table 7: Comparison of Detection Techniques  
Dilution IRIS Anti-
EBOV 
(Viruses/Spot) 
IRIS Anti-
LASV 
(Viruses/Spot) 
ELISA 
(RFU) 
Plaque 
Assay 
(PFU/mL) 
PCR 
(Average 
Cq.) 
1:5 1892 2 43823 1.5 x 107 9.98 
1:50 700 1 21824 1.7 x 106 16.49 
1:500 102 0 16663 1.5 x 105 19.64 
1:5000 18 4 15825 1.5 x 104 23.1 
Blank 3 1 14251 0 33.1 
 
Table 7 shows the results of the different techniques for virus detection shown in Figure 4. Numbers in red 
represent a positive test results and numbers in blue represent a negative test result. All tests except for the 
blank sample should be positive 
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is the most abundant of the viral proteins in Ebola Zaire strain[43].  In order to compare 
the IRIS disposable cartridge to the ReEbov Rapid Antigen Test, we used gamma 
irradiated Ebola (Zaire Strain-variant Mayinga) in cell culture media supplied by Rocky 
Mountain Laboratories. This sample was then diluted from the stock concentration in 
100% FBS and tested at four different concentrations ranging from 10-fold to 10,000-fold 
dilution. Both the IRIS disposable cartridge and the ReEbov Rapid Antigen Test were 
 
 
Dilution IRIS Anti-EBOV 
(Viruses Per Spot) 
IRIS Anti-LASV 
(Viruses Per Spot) 
ReEbov Test Strip 
1:10 1824 ** + 
1:100 393 4 + 
1:1000 126 -4 ? 
1:10000 29 4 - 
 
Figure 39: Comparison to Corgenix ReEbov Antigen Rapid Test 
Results of the IRIS test compared to the Corgenix ReEbov Antigen Rapid Test with samples of Gamma 
Irradiated Ebola Virus spiked into FBS. Figure 39A shows the results of the IRIS disposable cartridge with 
the number of viruses bound to the Anti-Ebola and Anti-Lassa antibodies. Figure 39B shows the results of 
the ReEbov Rapid Antigen test using the same samples tested in the IRIS cartridge. The results of the IRIS 
disposable cartridge as well as the Corgenix Rapid Antigen Test are shown in table form in which red 
represents a positive test results and blue represents a negative test result. 
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allowed to run for 20 minutes and were tested on the same sample. Figure 39A shows the 
number of viruses counted on both the anti-Ebola antibody as well as the anti- Lassa 
antibody in the IRIS cartridge. The red bars indicated positive detection of virions and 
correspond to the anti-Ebola antibody spots. The blue bars indicate negative for the 
presence of virions and correspond to the anti-Lassa antibody spots. The dotted line 
indicates the cut off for a positive signal. Figure 39B shows the results of the ReEbov 
Rapid Antigen Test.  The top red line is the control line and a positive test results in a 
secondary red line appearing below. The two highest concentration samples tested 
showed a clear positive signal. The third dilution tested was inconclusive, and the most 
dilute sample was negative. As shown in the table in Figure 39, the ReEbov test produced 
positive test results for the two highest concentrations, an inconclusive result for the 
concentration at 1000-fold dilution, and a negative result for the lowest concentration. 
The inconclusive result was caused by difficulty visualizing the red test line. Both 
positive and negative control tests were run as well (data not shown). The first two 
columns in the table in Figure 39 show the number of viruses detected on the anti-Ebola 
antibody and the anti-Lassa antibody respectively. The IRIS disposable cartridge showed 
a positive test results (shown in red) for all four concentrations tested, whereas the anti-
Lassa antibody showed negative results indicating good specificity. The right most 
column in the table in Figure 39 show the results of the ReEbov test portrayed as a yes/no 
answer. A red plus sign indicates yes, and a blue minus sign indicates no, with a question 
mark used for inconclusive results. These results suggest the IRIS disposable cartridge is 
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one to two orders of magnitude more sensitive than the ReEbov test strip under these test 
conditions.  
6.7. Bona Fide Ebola Testing 
To further validate the functionality of the platform beyond the model virus, testing 
was conducting using Ebola Virus, Zaire Strain-variant Mayinga, at the biosafety level 4 
facility of University of Texas Medical Branch in Galveston, Texas. To carry out these 
tests, stock virus solution in cell media was diluted using 100% FBS. Final dilutions were 
tested at expected plaque assay values ranging from 1x104-1x107 PFU/mL. The same 
protocol was used from previous experiments, using 100 µL of sample added to the 
cartridge reservoir and a 20 minute experimental time. Figure 40 shows the output of the 
analysis with the highest concentration tested at 1x107 PFU/mL. Data was acquired 
approximately every 2 minutes for 3 spots each of multiple different antibodies. The anti-
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Figure 40: High Concentration Bona Fide Ebola Test 
The highest concentration tested using the hot Ebola virus in FBS  
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Ebola antibody shows rapid accumulation of hundreds of viruses, while the anti-Lassa 
antibody shows no apparent virus binding. This shows that Ebola virus particles are 
specifically captured by the corresponding antibody. Figure 41 shows the results of the 
dilution experiment using concentrations of 1x104 – 1x107 PFU/mL as well as a blank 
sample. The lowest concentration that showed clearly detectable virus binding greater 
than the blank sample in this experiment was 1 x 105 PFU/mL in just under 20 minutes. 
This represents a 10 fold improvement in sensitivity compared to the ReEbov Antigen 
Rapid Test and the Oraquick Ebola Rapid Antigen Test, which reported an analytical 
sensitivity of 1 x 106 PFU/mL and 1.64 x 106 PFU/mL respectively[44], [45].  This shows 
the model Ebola virus (rVSV-ZEBOV) used works as a test platform for assay 
development and the cartridge is capable of rapid detection of bona fide Ebola virus in a 
complex solution.  
0 5 1 0 1 5 2 0
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
T im e  (m in )
A
v
e
ra
g
e
 V
ir
u
s
 C
o
u
n
t 1 0
7
 P F U /m L
10
6
 P F U /m L
10
5
 P F U /m L
10
4
 P F U /m L
B la nk
 
Figure 41: Bona Fide Ebola Dilution Experiment 
The full range of dilutions tested using the hot Ebola virus samples  
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An additional advantage of IRIS is that virus morphology can also be identified. 
Figure 42 highlights the increased information provided.  Figure 42A shows one EBOV 
capture spot. The perimeter of the spot is denoted with a red circle. The spot shows 
hundreds of virus particles of various shapes and sizes in a single image. Figure 42B 
shows an inset of the antibody spot highlighting the different populations of virus 
particles captured. This image dramatically increases confidence that EBOV is being 
captured and counted. There are many filamentous particles clearly visible. These 
particles vary in length (consistent with the potential for EBOV to be polyploid) and 
range from 1 to several microns.  Moreover, filamentous virus particles captured on the 
surface tend to align with the direction of flow, making their size and shape easier to 
determine. Figure 43C shows a close up of a 5 µm filamentous particle exhibiting the 
 
 
Figure 42: IRIS Images of Captured EBOV  
IRIS images of captured EBOV. A) shows viruses immobilized following a 20 minute assay. The red circle 
drawn outlines the perimeter of the antibody spot, particles are visible in false-color based on normalized 
pixel intensity. B) shows a zoomed area of interest. This image shows the polydispersity of the population 
of viruses captured from the sample, and shows clear evidence of filamentous particles. C) shows a close up 
of a 5 µm long filamentous virus particle exhibiting the quintessential shepherd’s crook shape of an Ebola 
virion. D) shows a shorter 1 µm long filamentous particle. E)  an example of the smaller spherical particles 
also seen. 
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stereotypical EBOV morphology. Figure 42D shows an example of a 1 µm filamentous 
Ebola particle that appears to be a more abundant among the population shown. Figure 
43E shows a close up of what appears to be a spherical particle. The additional 
information gleaned from the images of the virus increase confidence that the particles 
captured are in fact Ebola virions.  
Figure 43 shows an IRIS image of bona fide Marburg virus tested concurrently at 
UTMB. It is interesting to note the difference in morphology of the viruses. It is expected 
that Marburg virus is less frequently polyploid than Ebola virus which results in fewer 
long filaments which we see here. Additionally Marburg virus filaments are known to 
curl up creating O-shapes which would result in a higher intensity (larger) spherical 
particle on the IRIS image, also consistent with what is shown here. Thus, the 
enumeration of virus particles and characterization of morphology and polydispersity of a 
large number of particles is provided in a single approach.  
 
 
Figure 43: IRIS Images of Captured MARV 
IRIS images of captured Marburg Virus showing fewer filaments than Ebola. 
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7. CHAPTER SEVEN: CONCLUSION 
7.1. Discussion 
The real-time optical detection and spatial localization of individual viruses and 
nanoparticles has many applications beyond that of diagnostics. Real-time, sensitive, 
label-free detection of pathogens and nanoparticles can be used for bio-aerosol detection, 
environmental contamination monitoring, and basic virology research[46],[47]. Rapid and 
accurate quantification of multiple viruses is not only important for clinical diagnosis but 
for virology research as well. The ability to simultaneously identify and distinguish 
between multiple viruses in a single sample is necessary to treat patients appropriately. 
For example, many diseases present with similar symptoms, and the ability to 
differentiate between pathogens is necessary to ensure that proper care is given. 
Rapid diagnosis and intervention at the point-of-care is an invaluable tool in the 
detection and containment of disease. However, timely test results continue to be one of 
the main bottlenecks in the treatment of patients. We have demonstrated a platform 
capable of sensitive and specific label-free detection of viruses using a disposable 
cartridge and reader. This platform allows semi-quantitative results in a time comparable 
to lateral flow assays, as opposed to the traditional yes/no answer obtained from other 
rapid tests. This system exemplifies the compromise of a disposable cartridge with a 
reader that allows high performance without the infrastructure or user expertise required 
for a central laboratory test. Additionally, since the sample and waste are contained 
within the cartridge the reader does not need to be cleaned and the chance of accidental 
exposure is reduced. The disposable polymer cartridge protects the sensor during 
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shipment and the microarray stabilizer allows the test to be stored at room temperature 
removing the need for a cold chain. The IRIS disposable cartridge promises to be a high-
performance, inexpensive, and easy-to-use rapid test platform. 
To demonstrate the capability of this technique, samples were tested and 
compared to results from ELISA, PCR, plaque assay, and the ReEbov Rapid Antigen 
Test. This IRIS disposable cartridge platform shows promising performance compared to 
standard ELISA, PCR, and plaque assay using an Ebola GP-pseudotyped VSV model 
virus, outperforming the ELISA test in a shorter time. The IRIS disposable cartridge was 
also compared to the results of the ReEbov Rapid Antigen Test using gamma irradiated 
Ebola virus in 100% FBS. These results showed superior detection limit performance, 
with a detection limit 10-100 times more sensitive than the rapid test, while requiring no 
sample preparation or cold chain storage. The IRIS disposable cartridge was shown to be 
capable of rapidly detecting bona fide Ebola virions in complex solution, supporting that 
the model virus (rVSV-ZEBOV) was an appropriate test platform for assay development.  
Furthermore, individual particle size and shape can be assessed on a large number of 
viruses providing an additional dimension of information that is not provided by any of 
the standard laboratory or rapid tests. This IRIS disposable cartridge represents a new 
platform for rapid, semi-quantitative detection and characterization of viruses with 
promising potential for rapid diagnostics as well as virology research.  
7.2. Future Work 
 The development of a disposable cartridge opens up many new possibilities for 
this technology. First and foremost is the ability to translate the use of this test platform 
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out of our laboratory into the hands of researchers and clinicians. The testing on viral 
hemorrhagic fevers needs to be continued in collaboration with UTMB. This includes 
testing primate and human samples. Further antibody discovery will be needed to 
improve the detection of the newest strain of Ebola, Makona.  
 Additional cartridge designs that decrease the cost for research purposes will be of 
great use, and are already being explored. Cost reduction for this cartridge will be an area 
that needs significant work. Reducing the cost of the cartridge will allow much faster test 
development in the lab.  
 The further modelling and exploration of the phenomena associated with the 
functional affinity of nanoparticles is perhaps the most scientifically exciting area of 
research. The effects of the individual underlying phenomenon that impact the binding of 
particles to a surface will be of interest to a wider community of researchers. Both for 
biosensor development as well as microbiology research, and drug delivery. To tease 
apart the effects of particle size, flow rate, target and ligand density, and the other factors 
that impact the surface capture will be elucidating.  
 A method of improving the sensitivity for this assay would do a great deal to 
improve the technology. The sensor already has the ability to detect single particles, so 
the detector cannot be made more sensitive. However the surface capture efficiency is 
very low. Improving the surface capture could make this a disruptive sensing technology. 
There are several techniques that can be explored for this. Off chip concentration of 
nanoparticles is one approach. A more streamlined approach would be a method of 
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continuous concentration within the flow. Approaches that can be explored are the use of 
magnetic nanoparticles, dielectrophoresis, or microfluidic techniques.   
  
93 
PUBLICATIONS 
 
1. S. M. Scherr, G. G. Daaboul, J. Trueb, D. Sevenler, H. Fawcett, J. H. Connor, and M. 
S. Ünlu, “Real-Time Capture and Visualization of Individual Viruses in Com- plex 
Media,” ACS Nano, vol. 10, no. 2, pp. 2827–2833, 2016. 
2. E. Seymour, G. G. Daaboul, X. Zhang, S. M. Scherr, N. L. Ünlu, J. H. Connor, and 
M. S. Ünlü, “DNA-Directed Antibody Immobilization for Enhanced Detection of 
Single Viral Pathogens,” Anal. Chem., vol. 87, no. 20, pp. 10505–10512, 2015. 
3. S. M. Scherr, D. Freedman, K. Agans, A. Rosca, E. Carter, M. Kuroda, H. Fawcett, 
C. Mire, T. Geisbert, S. Unlu, J. H. Connor, “Disposable Cartridge Platform for Rapid 
Detection of Viral Hemorrhagic Fever Viruses,” Lab Chip, 2017, 17, 917–925. 
 
In Progress 
 
4. G.G. Daaboul, D. Freedman, S. M. Scherr, E. Carter, A. Rosca, D. Bernstein, C. 
Mires, K. Agans, T. Hoenen, H. Feldmann, T. Geidbert, M. S. Ünlü, “Enhanced Light 
Microscopy Visualization of Virus Particles from Zika Virus to filamentous 
Ebolaviruses,” PLOS ONE – under review 
5. On Chip Nanofluidic Pump for Automated Incubation and Detection of a 
Pseudotyped VSV Ebola Model 
6. Optimization of Microarray parameters for capture of Nanoparticles and Exosomes  
  
94 
BIBLIOGRAPHY 
 
[1] R. W. Peeling and D. Mabey, “Point-of-care tests for diagnosing infections in the 
developing world,” Clinical Microbiology and Infection, vol. 16, no. Imci, pp. 
1062–1069, 2010. 
[2] C. S. Goldsmith and S. E. Miller, “Modern Uses of Electron Microscopy for 
Detection of Viruses,” Clinical Microbiology Reviews, vol. 22, no. 4, pp. 552–563, 
Oct. 2009. 
[3] Y. G. Kuznetsov and A. McPherson, “Atomic Force Microscopy in Imaging of 
Viruses and Virus-Infected Cells,” Microbiology and Molecular Biology Reviews, 
vol. 75, no. 2, pp. 268–285, Jun. 2011. 
[4] C. a. Lopez, G. G. Daaboul, R. S. Vedula, E. Özkumur, D. a. Bergstein, T. W. 
Geisbert, H. E. Fawcett, B. B. Goldberg, J. H. Connor, and M. S. Ünlü, “Label-
free multiplexed virus detection using spectral reflectance imaging,” Biosensors 
and Bioelectronics, vol. 26, pp. 3432–3437, 2011. 
[5] G. G. Daaboul, C. A. Lopez, J. Chinnala, B. B. Goldberg, J. H. Connor, and M. 
Selim Ünlü, “Digital sensing and sizing of vesicular stomatitis virus pseudotypes 
in complex media: A model for ebola and marburg detection,” ACS Nano, vol. 8, 
no. 6, pp. 6047–6055, Jun. 2014. 
[6] G. G. Daaboul,  a. Yurt, X. Zhang, G. M. Hwang, B. B. Goldberg, and M. S. Ünlü, 
“High-throughput detection and sizing of individual low-index nanoparticles and 
viruses for pathogen identification,” Nano Letters, vol. 10, pp. 4727–4731, 2010. 
[7] “Viral Hemmoragic Fevers (VHFs),” Center for Disease Control and Prevention. 
[Online]. Available: https://www.cdc.gov/vhf/virus-families/index.html. 
[Accessed: 12-Dec-2016]. 
[8] N. Bhadelia, “Rapid diagnostics for Ebola in emergency settings,” The Lancet, vol. 
386, no. 9996, pp. 833–835, 2015. 
[9] J. B. McCormick, P. A. Webb, J. W. Krebs, K. M. Johnson, and E. S. Smith, “A 
prospective study of the epidemiology and ecology of Lassa fever,” Journal of 
Infectious Diseasers, vol. 155, no. 3, pp. 437–444, 1987. 
[10] B. Brandenburg and X. Zhuang, “Virus trafficking–learning from single-virus 
tracking,” Nature Reviews Microbiology, vol. 5, no. 3, pp. 197–208, 2007. 
[11] W. M. Chan, E. C. Bartee, J. S. Moreb, K. Dower, J. H. Connor, and G. 
  
95 
McFadden, “Myxoma and vaccinia viruses bind differentially to human 
leukocytes.,” Journal of virology, vol. 87, no. 8, pp. 4445–60, 2013. 
[12] P. Kramberger, M. Ciringer, A. Štrancar, and M. Peterka, “Evaluation of 
nanoparticle tracking analysis for total virus particle determination.,” Virology 
journal, vol. 9, no. 1, p. 265, 2012. 
[13] B. L. Gilmore, S. P. Showalter, M. J. Dukes, J. R. Tanner, A. C. Demmert, S. M. 
McDonald, and D. F. Kelly, “Visualizing viral assemblies in a nanoscale 
biosphere.,” Lab on a chip, vol. 13, no. 2, pp. 216–9, 2013. 
[14] C. Rossi, B. Kearney, S. Olschner, P. Williams, C. Robinson, M. Heinrich, A. 
Zovanyi, M. Ingram, D. Norwood, and R. Schoepp, “Evaluation of ViroCyt® 
Virus Counter for Rapid Filovirus Quantitation,” Viruses, vol. 7, no. 3, pp. 857–
872, 2015. 
[15] E. Garza-Licudine, D. Deo, S. Yu, A. Uz-Zaman, and W. B. Dunbar, “Portable 
nanoparticle quantization using a resizable nanopore instrument - The IZON 
qNanoTM,” 2010 Annual International Conference of the IEEE Engineering in 
Medicine and Biology Society, EMBC’10, pp. 5736–5739, 2010. 
[16] D. M. Jesus, N. Moussatche, B. B. D. McFadden, C. P. Nielsen, S. M. D’Costa, 
and R. C. Condit, “Vaccinia virus protein A3 is required for the production of 
normal immature virions and for the encapsidation of the nucleocapsid protein 
L4,” Virology, vol. 481, pp. 1–12, 2015. 
[17] S. Wang, X. Shan, U. Patel, X. Huang, J. Lu, J. Li, and N. Tao, “Label-free 
imaging, detection, and mass measurement of single viruses by surface plasmon 
resonance.,” Proceedings of the National Academy of Sciences of the United States 
of America, vol. 107, no. 37, pp. 16028–16032, 2010. 
[18] F. Vollmer and S. Arnold, “Whispering-gallery-mode biosensing: label-free 
detection down to single molecules.,” Nature methods, vol. 5, no. 7, pp. 591–596, 
2008. 
[19] Y. Zhuo, H. Hu, W. Chen, M. Lu, L. Tian, H. Yu, K. D. Long, E. Chow, W. P. 
King, S. Singamaneni, and B. T. Cunningham, “Single nanoparticle detection 
using photonic crystal enhanced microscopy.,” The Analyst, vol. 139, no. 5, pp. 
1007–15, 2014. 
[20] F. Akpinar and J. Yin, “Characterization of vesicular stomatitis virus populations 
by tunable resistive pulse sensing,” Journal of Virological Methods, vol. 218, pp. 
71–76, 2015. 
[21] V. Filipe, A. Hawe, and W. Jiskoot, “Critical evaluation of nanoparticle tracking 
  
96 
analysis (NTA) by NanoSight for the measurement of nanoparticles and protein 
aggregates,” Pharmaceutical Research, vol. 27, no. 5, pp. 796–810, 2010. 
[22] B. Mahy, Microbiology and Microbial Infection, 9th ed. Hodder Arnold, 1998. 
[23] D. Quesada-González and A. Merkoçi, “Nanoparticle-based lateral flow 
biosensors,” Biosensors and Bioelectronics, vol. 73, pp. 47–63, 2015. 
[24] M. F. Clark and A. N. Adams, “Characteristics of the microplate method of 
enzyme-linked immunosorbent assay for the detection of plant viruses.,” The 
Journal of general virology, vol. 34, no. 3, pp. 475–83, 1977. 
[25] M. Dulbecco, R.; Vogt, “Plaque Formation and Isolation of Pure Lines With 
Poliomyelitis Viruses,” Journal of Experimental Medicine, vol. 99, no. 2, pp. 167–
182, 1954. 
[26] S. L. Seurynck-Servoss, A. M. White, C. L. Baird, K. D. Rodland, and R. C. 
Zangar, “Evaluation of surface chemistries for antibody microarrays,” Analytical 
Biochemistry, vol. 371, no. 1, pp. 105–115, 2007. 
[27] E. Seymour, G. G. Daaboul, X. Zhang, S. M. Scherr, N. L. Ünlu, J. H. Connor, and 
M. S. Ünlu, “DNA-Directed Antibody Immobilization for Enhanced Detection of 
Single Viral Pathogens,” Analytical Chemistry, vol. 87, no. 20, pp. 10505–10512, 
2015. 
[28] M. Cretich, G. Pirri, F. Damin, I. Solinas, and M. Chiari, “A new polymeric 
coating for protein microarrays,” Analytical Biochemistry, vol. 332, pp. 67–74, 
2004. 
[29] D. Geißler, L. J. Charbonni, R. F. Ziessel, N. G. Butlin, H. Löhmannsröben, and N. 
Hildebrandt, “Quantum Dot Biosensors for Ultrasensitive Multiplexed Diagnostics 
** Angewandte,” pp. 1396–1401, 2010. 
[30] C. Yen, H. De Puig, J. O. Tam, J. Gómez-márquez, I. Bosch, K. Hamad-schifferli, 
and L. Gehrke, “Lab on a Chip disease diagnostics : distinguishing dengue , yellow 
fever , and Ebola viruses †,” Lab on a Chip, vol. 15, pp. 1638–1641, 2015. 
[31] J. B. Haun, L. R. Pepper, E. T. Boder, and D. A. Hammer, “Using engineered 
single-chain antibodies to correlate molecular binding properties and nanoparticle 
adhesion dynamics,” Langmuir, vol. 27, no. 22, pp. 13701–13712, 2011. 
[32] T. Sulchek, R. Friddle, T. Ratto, H. Albrecht, S. Denardo, and A. Noy, “Single-
molecule approach to understanding multivalent binding kinetics,” Annals of the 
New York Academy of Sciences, vol. 1161, pp. 74–82, 2009. 
  
97 
[33] J. Liu, R. Bradley, D. M. Eckmann, P. S. Ayyaswamy, and R. Radhakrishnan, 
“Multiscale Modeling of Functionalized Nanocarriers in Targeted Drug Delivery,” 
Current Nanoscience, vol. 7, no. 5, pp. 727–735, 2011. 
[34] J. B. Haun and D. A. Hammer, “Quantifying nanoparticle adhesion mediated by 
specific molecular interactions,” Langmuir, vol. 24, no. 16, pp. 8821–8832, 2008. 
[35] T. M. Squires, R. J. Messinger, and S. R. Manalis, “Making it stick: convection, 
reaction and diffusion in surface-based biosensors.,” Nature biotechnology, vol. 
26, no. 4, pp. 417–26, Apr. 2008. 
[36] H. Parsa, C. D. Chin, P. Mongkolwisetwara, B. W. Lee, J. J. Wang, and S. K. Sia, 
“Effect of volume- and time-based constraints on capture of analytes in 
microfluidic heterogeneous immunoassays.,” Lab on a chip, vol. 8, no. 12, pp. 
2062–70, Dec. 2008. 
[37] S. Byrnes, G. Thiessen, and E. Fu, “Progress in the development of paper-based 
diagnostics for low-resource point-of-care settings.,” Bioanalysis, vol. 5, no. 22, 
pp. 2821–36, 2013. 
[38] E. M. Fenton, M. R. Mascarenas, G. P. Lo, and S. S. Sibbett, “Multiplex Lateral-
Flow Test Strips Fabricated by Two-Dimensional Shaping,” Applied materials & 
Interfaces, vol. 1, no. 1, pp. 124–129, 2009. 
[39] S. Mendez, E. M. Fenton, G. R. Gallegos, D. N. Petsev, S. S. Sibbett, H. a Stone, 
Y. Zhang, and G. P. López, “Imbibition in porous membranes of complex shape: 
quasi-stationary flow in thin rectangular segments.,” Langmuir : the ACS journal 
of surfaces and colloids, vol. 26, no. 2, pp. 1380–5, Jan. 2010. 
[40] S. M. Scherr, D. S. Freedman, K. N. Agans, A. Rosca, E. Carter, M. Kuroda, H. E. 
Fawcett, C. E. Mire, T. W. Geisbert, M. S. Ünlü, and J. H. Connor, “Disposable 
cartridge platform for rapid detection of viral hemorrhagic fever viruses,” Lab 
Chip, vol. 17, pp. 917–925, 2017. 
[41] S. M. Scherr, G. G. Daaboul, J. Trueb, D. Sevenler, H. Fawcett, J. H. Connor, and 
M. S. Ünlu, “Real-Time Capture and Visualization of Individual Viruses in 
Complex Media,” ACS nano, vol. 10, no. 2, pp. 2827–2833, 2016. 
[42] D. A. Armbruster and T. Pry, “Limit of Blank , Limit of Detection and Limit of 
Quantitation,” Clinical Biochemist Reviews, vol. 29, no. August, pp. 49–52, 2008. 
[43] L. H. Elliot, M. P. Kiley, and J. B. McCormick, “Descriptive analysis of Ebola 
virus proteins,” Virology, vol. 147, no. 1, pp. 169–176, 1985. 
[44] R. W. Cross, M. L. Boisen, M. M. Millett, D. S. Nelson, D. Oottamasathien, J. N. 
  
98 
Hartnett, A. B. Jones, J. S. Schieffelin, B. Kargbo, M. Gbetuwa, S. M. Gevao, R. 
B. Wilson, E. O. Saphire, and K. R. Pitts, “Analytical Validation of the ReEBOV 
Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection,” The 
Journal of infectious diseases, vol. 214, no. Suppl 3, pp. 210–217, 2016. 
[45] “OraQuick Ebola Rapid Antigen Test,” Orasure Technologies, Inc., 2016. 
[Online]. Available: 
http://www.orasure.com/docs/pdfs/products/ebola/Ebola_Oral_Fluid_PI-ENG.pdf. 
[46] R. S. Salter, G. W. Durbin, E. Conklin, J. Rosen, and J. Clancy, “Proposed 
modifications of environmental protection agency method 1601 for detection of 
coliphages in drinking water, with same-day fluorescence-based detection and 
evaluation by the performance-based measurement system and alternative test 
protocol valida,” Applied and Environmental Microbiology, vol. 76, no. 23, pp. 
7803–7810, 2010. 
[47] T. M. Santiago-Rodríguez, C. Dávila, J. González, N. Bonilla, P. Marcos, M. 
Urdaneta, M. Cadete, S. Monteiro, R. Santos, J. S. Domingo, and G. a. Toranzos, 
“Characterization of Enterococcus faecalis-infecting phages (enterophages) as 
markers of human fecal pollution in recreational waters,” Water Research, vol. 44, 
pp. 4716–4725, 2010. 
 
  
 99 
CURRICULUM VITAE 
 100 
  
101 
 
